GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase)

 CDK2_HUMAN              Reviewed;         298 AA.
P24941; A8K7C6; O75100;
01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
01-AUG-1992, sequence version 2.
12-AUG-2020, entry version 249.
RecName: Full=Cyclin-dependent kinase 2;
EC=2.7.11.22 {ECO:0000269|PubMed:1396589, ECO:0000269|PubMed:28666995, ECO:0000269|PubMed:9030781};
AltName: Full=Cell division protein kinase 2;
AltName: Full=p33 protein kinase;
Name=CDK2; Synonyms=CDKN2;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=1714386; DOI=10.1002/j.1460-2075.1991.tb07808.x;
Elledge S.J., Spottswood M.R.;
"A new human p34 protein kinase, CDK2, identified by complementation of a
cdc28 mutation in Saccharomyces cerevisiae, is a homolog of Xenopus Eg1.";
EMBO J. 10:2653-2659(1991).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=1653904; DOI=10.1038/353174a0;
Tsai L.-H., Harlow E., Meyerson M.;
"Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus
E1A-associated p33 kinase.";
Nature 353:174-177(1991).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=1717994; DOI=10.1073/pnas.88.20.9006;
Ninomiya-Tsuji J., Nomoto S., Yasuda H., Reed S.I., Matsumoto K.;
"Cloning of a human cDNA encoding a CDC2-related kinase by complementation
of a budding yeast cdc28 mutation.";
Proc. Natl. Acad. Sci. U.S.A. 88:9006-9010(1991).
[4]
NUCLEOTIDE SEQUENCE (ISOFORM 2).
Nishikawa T., Ohta T., Fukuda M., Ogata H., Okamoto K., Isohashi F.,
Arima K., Yamaguchi S.;
"Sequence of deletion type cdk2 variant in human breast cancer.";
Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
Phelan M., Farmer A.;
"Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT SER-290.
NIEHS SNPs program;
Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=16541075; DOI=10.1038/nature04569;
Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
Gibbs R.A.;
"The finished DNA sequence of human chromosome 12.";
Nature 440:346-351(2006).
[9]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
Hunkapiller M.W., Myers E.W., Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[10]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
TISSUE=Placenta;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project:
the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[11]
CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT THR-14; TYR-15
AND THR-160, AND MUTAGENESIS OF THR-14; TYR-15 AND THR-160.
PubMed=1396589; DOI=10.1002/j.1460-2075.1992.tb05493.x;
Gu Y., Rosenblatt J., O'Morgan D.O.;
"Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and
Tyr15.";
EMBO J. 11:3995-4005(1992).
[12]
CATALYTIC ACTIVITY, AND ACTIVITY REGULATION BY ROSCOVITINE AND OLOMOUCINE.
PubMed=9030781; DOI=10.1111/j.1432-1033.1997.t01-2-00527.x;
Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N.,
Inagaki M., Delcros J.-G., Moulinoux J.-P.;
"Biochemical and cellular effects of roscovitine, a potent and selective
inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.";
Eur. J. Biochem. 243:527-536(1997).
[13]
FUNCTION AS RB1 KINASE, AND INTERACTION WITH CYCLIN E.
PubMed=10499802; DOI=10.1016/s0092-8674(00)81519-6;
Harbour J.W., Luo R.X., Dei Santi A., Postigo A.A., Dean D.C.;
"Cdk phosphorylation triggers sequential intramolecular interactions that
progressively block Rb functions as cells move through G1.";
Cell 98:859-869(1999).
[14]
FUNCTION AS NPM1 KINASE.
PubMed=11051553; DOI=10.1016/s0092-8674(00)00093-3;
Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K.,
Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., Fukasawa K.;
"Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome
duplication.";
Cell 103:127-140(2000).
[15]
FUNCTION AS NPAT KINASE.
PubMed=10995386; DOI=10.1101/gad.827700;
Zhao J., Kennedy B.K., Lawrence B.D., Barbie D.A., Matera A.G.,
Fletcher J.A., Harlow E.;
"NPAT links cyclin E-Cdk2 to the regulation of replication-dependent
histone gene transcription.";
Genes Dev. 14:2283-2297(2000).
[16]
FUNCTION AS NPAT KINASE, AND SUBCELLULAR LOCATION.
PubMed=10995387; DOI=10.1101/gad.829500;
Ma T., Van Tine B.A., Wei Y., Garrett M.D., Nelson D., Adams P.D., Wang J.,
Qin J., Chow L.T., Harper J.W.;
"Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in
Cajal bodies promotes histone gene transcription.";
Genes Dev. 14:2298-2313(2000).
[17]
FUNCTION AS P53/TP53 KINASE, AND INTERACTION WITH CYCLIN A AND CYCLIN B1.
PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
"The C-terminal regulatory domain of p53 contains a functional docking site
for cyclin A.";
J. Mol. Biol. 300:503-518(2000).
[18]
FUNCTION AS CDK7 KINASE, AND PHOSPHORYLATION BY CDK7.
PubMed=11113184; DOI=10.1128/mcb.21.1.88-99.2001;
Garrett S., Barton W.A., Knights R., Jin P., Morgan D.O., Fisher R.P.;
"Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by
substrate specificity determinants outside the T loop.";
Mol. Cell. Biol. 21:88-99(2001).
[19]
INTERACTION WITH CCNB3.
PubMed=12185076; DOI=10.1074/jbc.m203951200;
Nguyen T.B., Manova K., Capodieci P., Lindon C., Bottega S., Wang X.-Y.,
Refik-Rogers J., Pines J., Wolgemuth D.J., Koff A.;
"Characterization and expression of mammalian cyclin b3, a prepachytene
meiotic cyclin.";
J. Biol. Chem. 277:41960-41969(2002).
[20]
INTERACTION WITH SPDYA.
PubMed=11980914; DOI=10.1083/jcb.200109045;
Porter L.A., Dellinger R.W., Tynan J.A., Barnes E.A., Kong M.,
Lenormand J.-L., Donoghue D.J.;
"Human Speedy: a novel cell cycle regulator that enhances proliferation
through activation of Cdk2.";
J. Cell Biol. 157:357-366(2002).
[21]
INTERACTION WITH SPDYA.
PubMed=12839962;
Barnes E.A., Porter L.A., Lenormand J.-L., Dellinger R.W., Donoghue D.J.;
"Human Spy1 promotes survival of mammalian cells following DNA damage.";
Cancer Res. 63:3701-3707(2003).
[22]
FUNCTION.
PubMed=12944431; DOI=10.1242/dev.00731;
Terret M.E., Lefebvre C., Djiane A., Rassinier P., Moreau J., Maro B.,
Verlhac M.H.;
"DOC1R: a MAP kinase substrate that control microtubule organization of
metaphase II mouse oocytes.";
Development 130:5169-5177(2003).
[23]
INTERACTION WITH SPDYA, AND IDENTIFICATION IN A COMPLEX WITH CDKN1B AND
SPDYA.
PubMed=12972555; DOI=10.1091/mbc.e02-12-0820;
Porter L.A., Kong-Beltran M., Donoghue D.J.;
"Spy1 interacts with p27Kip1 to allow G1/S progression.";
Mol. Biol. Cell 14:3664-3674(2003).
[24]
INTERACTION WITH UHRF2, AND IDENTIFICATION IN A COMPLEX WITH UHRF2 AND
CCNE1.
PubMed=15178429; DOI=10.1016/j.bbrc.2004.04.190;
Li Y., Mori T., Hata H., Homma Y., Kochi H.;
"NIRF induces G1 arrest and associates with Cdk2.";
Biochem. Biophys. Res. Commun. 319:464-468(2004).
[25]
INTERACTION WITH CEBPA.
PubMed=15107404; DOI=10.1101/gad.1183304;
Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.;
"Liver tumors escape negative control of proliferation via PI3K/Akt-
mediated block of C/EBP alpha growth inhibitory activity.";
Genes Dev. 18:912-925(2004).
[26]
PHOSPHORYLATION AT THR-160.
PubMed=14597612; DOI=10.1074/jbc.m309995200;
Liu Y., Wu C., Galaktionov K.;
"p42, a novel cyclin-dependent kinase-activating kinase in mammalian
cells.";
J. Biol. Chem. 279:4507-4514(2004).
[27]
INTERACTION WITH SPDYA AND SPDYC.
PubMed=15611625; DOI=10.4161/cc.4.1.1347;
Cheng A., Xiong W., Ferrell J.E. Jr., Solomon M.J.;
"Identification and comparative analysis of multiple mammalian Speedy/Ringo
proteins.";
Cell Cycle 4:155-165(2005).
[28]
FUNCTION AS BRCA2 KINASE.
PubMed=15800615; DOI=10.1038/nature03404;
Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C.;
"CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for
recombinational repair.";
Nature 434:598-604(2005).
[29]
PHOSPHORYLATION BY CAK, MUTAGENESIS OF LYS-9; 88-LYS-LYS-89 AND LEU-166,
AND INTERACTION WITH CDK7.
PubMed=17373709; DOI=10.1002/prot.21370;
Lolli G., Johnson L.N.;
"Recognition of Cdk2 by Cdk7.";
Proteins 67:1048-1059(2007).
[30]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
Greff Z., Keri G., Stemmann O., Mann M.;
"Kinase-selective enrichment enables quantitative phosphoproteomics of the
kinome across the cell cycle.";
Mol. Cell 31:438-448(2008).
[31]
FUNCTION IN MITOSE REGULATION, AND SUBCELLULAR LOCATION.
PubMed=18372919; DOI=10.1038/onc.2008.74;
De Boer L., Oakes V., Beamish H., Giles N., Stevens F.,
Somodevilla-Torres M., Desouza C., Gabrielli B.;
"Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events.";
Oncogene 27:4261-4268(2008).
[32]
INTERACTION WITH CACUL1.
PubMed=19829063; DOI=10.4161/cc.8.21.9955;
Kong Y., Nan K., Yin Y.;
"Identification and characterization of CAC1 as a novel CDK2-associated
cullin.";
Cell Cycle 8:3552-3561(2009).
[33]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-19, AND IDENTIFICATION BY
MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
Mann M., Daub H.;
"Large-scale proteomics analysis of the human kinome.";
Mol. Cell. Proteomics 8:1751-1764(2009).
[34]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-15, AND IDENTIFICATION BY
MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Leukemic T-cell;
PubMed=19690332; DOI=10.1126/scisignal.2000007;
Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
Rodionov V., Han D.K.;
"Quantitative phosphoproteomic analysis of T cell receptor signaling
reveals system-wide modulation of protein-protein interactions.";
Sci. Signal. 2:RA46-RA46(2009).
[35]
ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-6, AND IDENTIFICATION BY MASS
SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=19608861; DOI=10.1126/science.1175371;
Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
Olsen J.V., Mann M.;
"Lysine acetylation targets protein complexes and co-regulates major
cellular functions.";
Science 325:834-840(2009).
[36]
FUNCTION IN VITAMIN D-MEDIATED GROWTH INHIBITION, SUBCELLULAR LOCATION,
ACTIVITY REGULATION, AND PHOSPHORYLATION AT THR-160.
PubMed=20147522; DOI=10.1210/en.2009-1116;
Flores O., Wang Z., Knudsen K.E., Burnstein K.L.;
"Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of
cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated
growth inhibition.";
Endocrinology 151:896-908(2010).
[37]
FUNCTION, AND S-NITROSYLATION.
PubMed=20079829; DOI=10.1016/j.freeradbiomed.2010.01.004;
Kumar S., Barthwal M.K., Dikshit M.;
"Cdk2 nitrosylation and loss of mitochondrial potential mediate NO-
dependent biphasic effect on HL-60 cell cycle.";
Free Radic. Biol. Med. 48:851-861(2010).
[38]
PHOSPHORYLATION AT THR-160 BY CAK, AND DEPHOSPHORYLATION BY CDC25A.
PubMed=20360007; DOI=10.1074/jbc.m109.096552;
Timofeev O., Cizmecioglu O., Settele F., Kempf T., Hoffmann I.;
"Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at
the G2/M transition.";
J. Biol. Chem. 285:16978-16990(2010).
[39]
FUNCTION AS EZH2 KINASE.
PubMed=20935635; DOI=10.1038/ncb2116;
Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A.,
Simon J.A., Huang H.;
"Cyclin-dependent kinases regulate epigenetic gene silencing through
phosphorylation of EZH2.";
Nat. Cell Biol. 12:1108-1114(2010).
[40]
FUNCTION IN DNA DAMAGE CHECKPOINT.
PubMed=20195506; DOI=10.1371/journal.pgen.1000863;
Chung J.H., Bunz F.;
"Cdk2 is required for p53-independent G2/M checkpoint control.";
PLoS Genet. 6:E1000863-E1000863(2010).
[41]
FUNCTION AS MYC KINASE.
PubMed=19966300; DOI=10.1073/pnas.0900121106;
Hydbring P., Bahram F., Su Y., Tronnersjoe S., Hoegstrand K.,
von der Lehr N., Sharifi H.R., Lilischkis R., Hein N., Wu S., Vervoorts J.,
Henriksson M., Grandien A., Luescher B., Larsson L.-G.;
"Phosphorylation by Cdk2 is required for Myc to repress Ras-induced
senescence in cotransformation.";
Proc. Natl. Acad. Sci. U.S.A. 107:58-63(2010).
[42]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21269460; DOI=10.1186/1752-0509-5-17;
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
Bennett K.L., Superti-Furga G., Colinge J.;
"Initial characterization of the human central proteome.";
BMC Syst. Biol. 5:17-17(2011).
[43]
INTERACTION WITH CEP63.
PubMed=21406398; DOI=10.1158/0008-5472.can-10-2684;
Loffler H., Fechter A., Matuszewska M., Saffrich R., Mistrik M.,
Marhold J., Hornung C., Westermann F., Bartek J., Kramer A.;
"Cep63 recruits Cdk1 to the centrosome: implications for regulation of
mitotic entry, centrosome amplification, and genome maintenance.";
Cancer Res. 71:2129-2139(2011).
[44]
FUNCTION AS CTNNB1 KINASE, SUBCELLULAR LOCATION, AND INTERACTION WITH PTPN6
AND CTNNB1.
PubMed=21262353; DOI=10.1016/j.cellsig.2011.01.019;
Fiset A., Xu E., Bergeron S., Marette A., Pelletier G., Siminovitch K.A.,
Olivier M., Beauchemin N., Faure R.L.;
"Compartmentalized CDK2 is connected with SHP-1 and beta-catenin and
regulates insulin internalization.";
Cell. Signal. 23:911-919(2011).
[45]
INHIBITORS.
PubMed=21684737; DOI=10.1016/j.bmcl.2011.05.081;
Lee J., Kim K.H., Jeong S.;
"Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2
inhibitors.";
Bioorg. Med. Chem. Lett. 21:4203-4205(2011).
[46]
FUNCTION AS USP37 KINASE.
PubMed=21596315; DOI=10.1016/j.molcel.2011.03.027;
Huang X., Summers M.K., Pham V., Lill J.R., Liu J., Lee G.,
Kirkpatrick D.S., Jackson P.K., Fang G., Dixit V.M.;
"Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and
promote S phase entry.";
Mol. Cell 42:511-523(2011).
[47]
FUNCTION IN CELL CYCLE REGULATION.
PubMed=21319273; DOI=10.1002/stem.620;
Neganova I., Vilella F., Atkinson S.P., Lloret M., Passos J.F.,
von Zglinicki T., O'Connor J.-E., Burks D., Jones R., Armstrong L.,
Lako M.;
"An important role for CDK2 in G1 to S checkpoint activation and DNA damage
response in human embryonic stem cells.";
Stem Cells 29:651-659(2011).
[48]
REVIEW ON DNA REPAIR, AND INTERACTION WITH CDKN1A/P21.
PubMed=19445729; DOI=10.1186/1747-1028-4-9;
Satyanarayana A., Kaldis P.;
"A dual role of Cdk2 in DNA damage response.";
Cell Div. 4:9-9(2009).
[49]
REVIEW ON CELL CYCLE CONTROL, INHIBITORS, AND GENE FAMILY.
PubMed=19238148; DOI=10.1038/nrc2602;
Malumbres M., Barbacid M.;
"Cell cycle, CDKs and cancer: a changing paradigm.";
Nat. Rev. Cancer 9:153-166(2009).
[50]
REVIEW, AND GENE FAMILY.
PubMed=19561645; DOI=10.1038/onc.2009.170;
Satyanarayana A., Kaldis P.;
"Mammalian cell-cycle regulation: several Cdks, numerous cyclins and
diverse compensatory mechanisms.";
Oncogene 28:2925-2939(2009).
[51]
REVIEW ON SENESCENCE.
PubMed=20713526; DOI=10.1158/0008-5472.can-10-1383;
Hydbring P., Larsson L.-G.;
"Tipping the balance: Cdk2 enables Myc to suppress senescence.";
Cancer Res. 70:6687-6691(2010).
[52]
REVIEW ON INHIBITORS.
PubMed=21517772; DOI=10.2174/092986711795590110;
Wang Q., Su L., Liu N., Zhang L., Xu W., Fang H.;
"Cyclin dependent kinase 1 inhibitors: a review of recent progress.";
Curr. Med. Chem. 18:2025-2043(2011).
[53]
ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=22814378; DOI=10.1073/pnas.1210303109;
Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
"N-terminal acetylome analyses and functional insights of the N-terminal
acetyltransferase NatB.";
Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
[54]
INTERACTION WITH CYCLIN E; CYCLIN A AND CDK2AP2, AND PHOSPHORYLATION.
PubMed=23781148; DOI=10.7150/ijbs.5763;
Liu Q., Liu X., Gao J., Shi X., Hu X., Wang S., Luo Y.;
"Overexpression of DOC-1R inhibits cell cycle G1/S transition by repressing
CDK2 expression and activation.";
Int. J. Biol. Sci. 9:541-549(2013).
[55]
FUNCTION.
PubMed=29203878; DOI=10.1038/s41467-017-02114-x;
Batenburg N.L., Walker J.R., Noordermeer S.M., Moatti N., Durocher D.,
Zhu X.D.;
"ATM and CDK2 control chromatin remodeler CSB to inhibit RIF1 in DSB repair
pathway choice.";
Nat. Commun. 8:1921-1921(2017).
[56]
X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
PubMed=8510751; DOI=10.1038/363595a0;
de Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O.,
Kim S.-H.;
"Crystal structure of cyclin-dependent kinase 2.";
Nature 363:595-602(1993).
[57]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH CYCLIN A.
PubMed=7630397; DOI=10.1038/376313a0;
Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massague J.,
Pavletich N.P.;
"Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2
complex.";
Nature 376:313-320(1995).
[58]
X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITG CKS1.
PubMed=8601310; DOI=10.1016/s0092-8674(00)81065-x;
Bourne Y., Watson M.H., Hickey M.J., Holmes W., Rocque W., Reed S.I.,
Tainer J.A.;
"Crystal structure and mutational analysis of the human CDK2 kinase complex
with cell cycle-regulatory protein CksHs1.";
Cell 84:863-874(1996).
[59]
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
PubMed=8917641; DOI=10.1021/jm960402a;
Schulze-Gahmen U., de Bondt H.L., Kim S.-H.;
"High-resolution crystal structures of human cyclin-dependent kinase 2 with
and without ATP: bound waters and natural ligand as guides for inhibitor
design.";
J. Med. Chem. 39:4540-4546(1996).
[60]
X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEX WITH CCNA2 AND CDKN1B.
PubMed=8684460; DOI=10.1038/382325a0;
Russo A.A., Jeffrey P.D., Patten A.K., Massague J., Pavletich N.P.;
"Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound
to the cyclin A-Cdk2 complex.";
Nature 382:325-331(1996).
[61]
X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEX WITH CG2A.
PubMed=8756328; DOI=10.1038/nsb0896-696;
Russo A.A., Jeffrey P.D., Pavletich N.P.;
"Structural basis of cyclin-dependent kinase activation by
phosphorylation.";
Nat. Struct. Biol. 3:696-700(1996).
[62]
X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) IN COMPLEX WITH L868276.
PubMed=8610110; DOI=10.1073/pnas.93.7.2735;
de Azevedo W.F. Jr., Mueller-Dieckmann H.-J., Schulze-Gahmen U.,
Worland P.J., Sausville E., Kim S.-H.;
"Structural basis for specificity and potency of a flavonoid inhibitor of
human CDK2, a cell cycle kinase.";
Proc. Natl. Acad. Sci. U.S.A. 93:2735-2740(1996).
[63]
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) IN COMPLEX WITH STAUROSPORINE, AND
ACTIVITY REGULATION.
PubMed=9334743; DOI=10.1038/nsb1097-796;
Lawrie A.M., Noble M.E.M., Tunnah P., Brown N.R., Johnson L.N.,
Endicott J.A.;
"Protein kinase inhibition by staurosporine revealed in details of the
molecular interaction with CDK2.";
Nat. Struct. Biol. 4:796-801(1997).
[64]
X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS).
PubMed=9677190; DOI=10.1126/science.281.5376.533;
Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Norman T.C., Kwon S.,
Espinoza F.H., Morgan D.O., Barnes G., Leclerc S., Meijer L., Kim S.H.,
Lockhart D.J., Schultz P.G.;
"Exploiting chemical libraries, structure, and genomics in the search for
kinase inhibitors.";
Science 281:533-538(1998).
[65]
X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
PHOSPHORYLATION AT THR-160.
PubMed=16325401; DOI=10.1016/j.bmcl.2005.11.048;
Richardson C.M., Williamson D.S., Parratt M.J., Borgognoni J.,
Cansfield A.D., Dokurno P., Francis G.L., Howes R., Moore J.D.,
Murray J.B., Robertson A., Surgenor A.E., Torrance C.J.;
"Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-
guided design and SAR.";
Bioorg. Med. Chem. Lett. 16:1353-1357(2006).
[66]
X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
PHOSPHORYLATION AT THR-160.
PubMed=17570665; DOI=10.1016/j.bmcl.2007.04.110;
Richardson C.M., Nunns C.L., Williamson D.S., Parratt M.J., Dokurno P.,
Howes R., Borgognoni J., Drysdale M.J., Finch H., Hubbard R.E.,
Jackson P.S., Kierstan P., Lentzen G., Moore J.D., Murray J.B.,
Simmonite H., Surgenor A.E., Torrance C.J.;
"Discovery of a potent CDK2 inhibitor with a novel binding mode, using
virtual screening and initial, structure-guided lead scoping.";
Bioorg. Med. Chem. Lett. 17:3880-3885(2007).
[67]
X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 1-288 IN COMPLEX WITH CCNB1, AND
FUNCTION.
PubMed=17495531; DOI=10.4161/cc.6.11.4278;
Brown N.R., Lowe E.D., Petri E., Skamnaki V., Antrobus R., Johnson L.N.;
"Cyclin B and cyclin A confer different substrate recognition properties on
CDK2.";
Cell Cycle 6:1350-1359(2007).
[68]
X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) IN COMPLEX WITH ATP, AND
PHOSPHORYLATION AT THR-14; TYR-15 AND THR-160.
PubMed=17095507; DOI=10.1074/jbc.m609151200;
Welburn J.P.I., Tucker J.A., Johnson T., Lindert L., Morgan M., Willis A.,
Noble M.E.M., Endicott J.A.;
"How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent
kinase 2-cyclin A.";
J. Biol. Chem. 282:3173-3181(2007).
[69]
X-RAY CRYSTALLOGRAPHY (1.28 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
PubMed=17937404; DOI=10.1002/bip.20868;
Fischmann T.O., Hruza A., Duca J.S., Ramanathan L., Mayhood T.,
Windsor W.T., Le H.V., Guzi T.J., Dwyer M.P., Paruch K., Doll R.J.,
Lees E., Parry D., Seghezzi W., Madison V.;
"Structure-guided discovery of cyclin-dependent kinase inhibitors.";
Biopolymers 89:372-379(2008).
[70]
X-RAY CRYSTALLOGRAPHY (1.68 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
PubMed=18656911; DOI=10.1021/jm800382h;
Wyatt P.G., Woodhead A.J., Berdini V., Boulstridge J.A., Carr M.G.,
Cross D.M., Davis D.J., Devine L.A., Early T.R., Feltell R.E., Lewis E.J.,
McMenamin R.L., Navarro E.F., O'Brien M.A., O'Reilly M., Reule M.,
Saxty G., Seavers L.C., Smith D.M., Squires M.S., Trewartha G.,
Walker M.T., Woolford A.J.;
"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-
pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor
using fragment-based X-ray crystallography and structure based drug
design.";
J. Med. Chem. 51:4986-4999(2008).
[71]
X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 1-296 IN COMPLEX WITH ATP AND
MAGNESIUM, COFACTOR, AND PHOSPHORYLATION AT THR-160.
PubMed=21565702; DOI=10.1016/j.str.2011.02.016;
Bao Z.Q., Jacobsen D.M., Young M.A.;
"Briefly bound to activate: transient binding of a second catalytic
magnesium activates the structure and dynamics of CDK2 kinase for
catalysis.";
Structure 19:675-690(2011).
[72] {ECO:0000244|PDB:5UQ1, ECO:0000244|PDB:5UQ2, ECO:0000244|PDB:5UQ3}
X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) IN COMPLEXES WITH SPDYA AND CDKN1B,
FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, INTERACTION WITH SPDYA
AND CDKN1B, AND PHOSPHORYLATION AT THR-160.
PubMed=28666995; DOI=10.15252/embj.201796905;
McGrath D.A., Fifield B.A., Marceau A.H., Tripathi S., Porter L.A.,
Rubin S.M.;
"Structural basis of divergent cyclin-dependent kinase activation by
Spy1/RINGO proteins.";
EMBO J. 36:2251-2262(2017).
[73]
VARIANTS [LARGE SCALE ANALYSIS] LEU-45 AND SER-290.
PubMed=17344846; DOI=10.1038/nature05610;
Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
Futreal P.A., Stratton M.R.;
"Patterns of somatic mutation in human cancer genomes.";
Nature 446:153-158(2007).
[74]
INTERACTION WITH ANKRD17.
PubMed=23711367; DOI=10.1016/j.febslet.2013.05.037;
Menning M., Kufer T.A.;
"A role for the Ankyrin repeat containing protein Ankrd17 in Nod1- and
Nod2-mediated inflammatory responses.";
FEBS Lett. 587:2137-2142(2013).
-!- FUNCTION: Serine/threonine-protein kinase involved in the control of
the cell cycle; essential for meiosis, but dispensable for mitosis.
Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC,
NPAT, EZH2. Triggers duplication of centrosomes and DNA. Acts at the
G1-S transition to promote the E2F transcriptional program and the
initiation of DNA synthesis, and modulates G2 progression; controls the
timing of entry into mitosis/meiosis by controlling the subsequent
activation of cyclin B/CDK1 by phosphorylation, and coordinates the
activation of cyclin B/CDK1 at the centrosome and in the nucleus.
Crucial role in orchestrating a fine balance between cellular
proliferation, cell death, and DNA repair in human embryonic stem cells
(hESCs). Activity of CDK2 is maximal during S phase and G2; activated
by interaction with cyclin E during the early stages of DNA synthesis
to permit G1-S transition, and subsequently activated by cyclin A2
(cyclin A1 in germ cells) during the late stages of DNA replication to
drive the transition from S phase to mitosis, the G2 phase. EZH2
phosphorylation promotes H3K27me3 maintenance and epigenetic gene
silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2
prevents oxidative stress-mediated Ras-induced senescence by
phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that
prevents cells with damaged DNA from initiating mitosis; regulates
homologous recombination-dependent repair by phosphorylating BRCA2,
this phosphorylation is low in S phase when recombination is active,
but increases as cells progress towards mitosis. In response to DNA
damage, double-strand break repair by homologous recombination a
reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of
RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin
E/CDK2 promotes its dissociates from unduplicated centrosomes, thus
initiating centrosome duplication. Cyclin E/CDK2-mediated
phosphorylation of NPAT at G1-S transition and until prophase
stimulates the NPAT-mediated activation of histone gene transcription
during S phase. Required for vitamin D-mediated growth inhibition by
being itself inactivated. Involved in the nitric oxide- (NO) mediated
signaling in a nitrosylation/activation-dependent manner. USP37 is
activated by phosphorylation and thus triggers G1-S transition. CTNNB1
phosphorylation regulates insulin internalization. Phosphorylates FOXP3
and negatively regulates its transcriptional activity and protein
stability (By similarity). Phosphorylates CDK2AP2 (PubMed:12944431).
Phosphorylates ERCC6 which is essential for its chromatin remodeling
activity at DNA double-strand breaks (PubMed:29203878).
{ECO:0000250|UniProtKB:P97377, ECO:0000269|PubMed:10499802,
ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10995386,
ECO:0000269|PubMed:10995387, ECO:0000269|PubMed:11051553,
ECO:0000269|PubMed:11113184, ECO:0000269|PubMed:12944431,
ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:17495531,
ECO:0000269|PubMed:18372919, ECO:0000269|PubMed:19966300,
ECO:0000269|PubMed:20079829, ECO:0000269|PubMed:20147522,
ECO:0000269|PubMed:20195506, ECO:0000269|PubMed:20935635,
ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21319273,
ECO:0000269|PubMed:21596315, ECO:0000269|PubMed:28666995,
ECO:0000269|PubMed:29203878}.
-!- CATALYTIC ACTIVITY:
Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
[protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
Evidence={ECO:0000269|PubMed:1396589, ECO:0000269|PubMed:28666995,
ECO:0000269|PubMed:9030781};
-!- CATALYTIC ACTIVITY:
Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
EC=2.7.11.22; Evidence={ECO:0000269|PubMed:1396589,
ECO:0000269|PubMed:28666995, ECO:0000269|PubMed:9030781};
-!- COFACTOR:
Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
Evidence={ECO:0000269|PubMed:21565702};
Note=Binds 2 Mg(2+) ions. {ECO:0000269|PubMed:21565702};
-!- ACTIVITY REGULATION: Phosphorylation at Thr-14 or Tyr-15 inactivates
the enzyme, while phosphorylation at Thr-160 activates it
(PubMed:1396589). Inhibited by 1,25-dihydroxyvitamin D(3) (1,25-
(OH)(2)D(3)), AG-024322, N-(4-Piperidinyl)-4-(2,6-
dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), R547 (Ro-
4584820), purine, pyrimidine and pyridine derivatives, 2-
aminopyrimidines, paullones, thiazo derivatives, macrocyclic
quinoxalin-2-one, pyrazolo[1,5-a]-1,3,5-triazine, pyrazolo[1,5-
a]pyrimidine, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-
isopropylpurine (roscovitine, seliciclib and CYC202), SNS-032 (BMS-
387032), triazolo[1,5-a]pyrimidines, staurosporine and olomoucine.
Stimulated by MYC. Inactivated by CDKN1A (p21).
{ECO:0000269|PubMed:1396589, ECO:0000269|PubMed:20147522,
ECO:0000269|PubMed:28666995, ECO:0000269|PubMed:9030781,
ECO:0000269|PubMed:9334743}.
-!- SUBUNIT: Found in a complex with CABLES1, CCNA1 and CCNE1. Interacts
with CABLES1 (By similarity). Interacts with UHRF2. Part of a complex
consisting of UHRF2, CDK2 and CCNE1. Interacts with the Speedy/Ringo
proteins SPDYA and SPDYC (PubMed:15611625). Interaction with SPDYA
promotes kinase activation via a conformation change that alleviates
obstruction of the substrate-binding cleft by the T-loop
(PubMed:28666995). Found in a complex with both SPDYA and CDKN1B/KIP1
(PubMed:12972555, PubMed:28666995). Binds to RB1 and CDK7. Binding to
CDKN1A (p21) leads to CDK2/cyclin E inactivation at the G1-S phase DNA
damage checkpoint, thereby arresting cells at the G1-S transition
during DNA repair. Associated with PTPN6 and beta-catenin/CTNNB1.
Interacts with CACUL1. May interact with CEP63. Interacts with ANKRD17.
Interacts with CEBPA (when phosphorylated) (PubMed:15107404). Forms a
ternary complex with CCNA2 and CDKN1B; CDKN1B inhibits the kinase
activity of CDK2 through conformational rearrangements
(PubMed:8684460). Interacts with cyclins A, B1, B3, D, or E
(PubMed:10499802, PubMed:10884347, PubMed:12185076, PubMed:23781148).
Interacts with CDK2AP2 (PubMed:23781148).
{ECO:0000250|UniProtKB:P97377, ECO:0000250|UniProtKB:Q63699,
ECO:0000269|PubMed:10499802, ECO:0000269|PubMed:10884347,
ECO:0000269|PubMed:11980914, ECO:0000269|PubMed:12185076,
ECO:0000269|PubMed:12839962, ECO:0000269|PubMed:12972555,
ECO:0000269|PubMed:15107404, ECO:0000269|PubMed:15178429,
ECO:0000269|PubMed:15611625, ECO:0000269|PubMed:16325401,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:17373709,
ECO:0000269|PubMed:17495531, ECO:0000269|PubMed:17570665,
ECO:0000269|PubMed:17937404, ECO:0000269|PubMed:18656911,
ECO:0000269|PubMed:19445729, ECO:0000269|PubMed:19829063,
ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21406398,
ECO:0000269|PubMed:21565702, ECO:0000269|PubMed:23711367,
ECO:0000269|PubMed:23781148, ECO:0000269|PubMed:28666995,
ECO:0000269|PubMed:7630397, ECO:0000269|PubMed:8610110,
ECO:0000269|PubMed:8684460, ECO:0000269|PubMed:8756328,
ECO:0000269|PubMed:9334743}.
-!- INTERACTION:
P24941; P20248: CCNA2; NbExp=27; IntAct=EBI-375096, EBI-457097;
P24941; O95067: CCNB2; NbExp=4; IntAct=EBI-375096, EBI-375024;
P24941; P24385: CCND1; NbExp=4; IntAct=EBI-375096, EBI-375001;
P24941; P24864: CCNE1; NbExp=19; IntAct=EBI-375096, EBI-519526;
P24941; O96020: CCNE2; NbExp=11; IntAct=EBI-375096, EBI-375033;
P24941; P51946: CCNH; NbExp=4; IntAct=EBI-375096, EBI-741406;
P24941; P50613: CDK7; NbExp=3; IntAct=EBI-375096, EBI-1245958;
P24941; P38936: CDKN1A; NbExp=28; IntAct=EBI-375096, EBI-375077;
P24941; P46527: CDKN1B; NbExp=25; IntAct=EBI-375096, EBI-519280;
P24941; Q16667: CDKN3; NbExp=7; IntAct=EBI-375096, EBI-1031527;
P24941; P61024: CKS1B; NbExp=20; IntAct=EBI-375096, EBI-456371;
P24941; Q09472: EP300; NbExp=6; IntAct=EBI-375096, EBI-447295;
P24941; Q969H0-4: FBXW7; NbExp=2; IntAct=EBI-375096, EBI-6502391;
P24941; Q9Y6K9: IKBKG; NbExp=4; IntAct=EBI-375096, EBI-81279;
P24941; O95835: LATS1; NbExp=4; IntAct=EBI-375096, EBI-444209;
P24941; Q8TD08: MAPK15; NbExp=4; IntAct=EBI-375096, EBI-1383794;
P24941; P06400: RB1; NbExp=3; IntAct=EBI-375096, EBI-491274;
P24941; Q9BY12: SCAPER; NbExp=3; IntAct=EBI-375096, EBI-308519;
P24941; Q9UQR0: SCML2; NbExp=3; IntAct=EBI-375096, EBI-2513111;
P24941; Q9UQR0-1: SCML2; NbExp=7; IntAct=EBI-375096, EBI-16087037;
P24941; Q9UBI4: STOML1; NbExp=2; IntAct=EBI-375096, EBI-2681162;
P24941; Q96PU4: UHRF2; NbExp=5; IntAct=EBI-375096, EBI-625304;
P24941; P30274: CCNA2; Xeno; NbExp=2; IntAct=EBI-375096, EBI-15688654;
P24941; P51943: Ccna2; Xeno; NbExp=2; IntAct=EBI-375096, EBI-846980;
P24941; P03129: E7; Xeno; NbExp=2; IntAct=EBI-375096, EBI-866453;
P24941; Q08619: Ifi205b; Xeno; NbExp=2; IntAct=EBI-375096, EBI-8064290;
-!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
center, centrosome. Nucleus, Cajal body. Cytoplasm. Endosome.
Note=Localized at the centrosomes in late G2 phase after separation of
the centrosomes but before the start of prophase. Nuclear-cytoplasmic
trafficking is mediated during the inhibition by 1,25-(OH)(2)D(3).
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=1;
IsoId=P24941-1; Sequence=Displayed;
Name=2; Synonyms=CDK2deltaT;
IsoId=P24941-2; Sequence=VSP_041998;
-!- INDUCTION: Induced transiently by TGFB1 at an early phase of TGFB1-
mediated apoptosis.
-!- PTM: Phosphorylated at Thr-160 by CDK7 in a CAK complex
(PubMed:28666995). Phosphorylation at Thr-160 promotes kinase activity,
whereas phosphorylation at Tyr-15 by WEE1 reduces slightly kinase
activity. Phosphorylated on Thr-14 and Tyr-15 during S and G2 phases
before being dephosphorylated by CDC25A. {ECO:0000269|PubMed:11113184,
ECO:0000269|PubMed:1396589, ECO:0000269|PubMed:14597612,
ECO:0000269|PubMed:16325401, ECO:0000269|PubMed:17095507,
ECO:0000269|PubMed:17373709, ECO:0000269|PubMed:17570665,
ECO:0000269|PubMed:20147522, ECO:0000269|PubMed:20360007,
ECO:0000269|PubMed:21565702, ECO:0000269|PubMed:23781148,
ECO:0000305|PubMed:28666995}.
-!- PTM: Nitrosylated after treatment with nitric oxide (DETA-NO).
{ECO:0000269|PubMed:20079829}.
-!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
-!- WEB RESOURCE: Name=NIEHS-SNPs;
URL="http://egp.gs.washington.edu/data/cdk2/";
---------------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
---------------------------------------------------------------------------
EMBL; X61622; CAA43807.1; -; mRNA.
EMBL; X62071; CAA43985.1; -; mRNA.
EMBL; M68520; AAA35667.1; -; mRNA.
EMBL; AB012305; BAA32794.1; -; mRNA.
EMBL; BT006821; AAP35467.1; -; mRNA.
EMBL; AF512553; AAM34794.1; -; Genomic_DNA.
EMBL; AK291941; BAF84630.1; -; mRNA.
EMBL; AC025162; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; AC034102; -; NOT_ANNOTATED_CDS; Genomic_DNA.
EMBL; CH471054; EAW96858.1; -; Genomic_DNA.
EMBL; BC003065; AAH03065.1; -; mRNA.
CCDS; CCDS8898.1; -. [P24941-1]
CCDS; CCDS8899.1; -. [P24941-2]
PIR; A41227; A41227.
RefSeq; NP_001277159.1; NM_001290230.1.
RefSeq; NP_001789.2; NM_001798.4. [P24941-1]
RefSeq; NP_439892.2; NM_052827.3. [P24941-2]
PDB; 1AQ1; X-ray; 2.00 A; A=1-298.
PDB; 1B38; X-ray; 2.00 A; A=1-298.
PDB; 1B39; X-ray; 2.10 A; A=1-298.
PDB; 1BUH; X-ray; 2.60 A; A=1-298.
PDB; 1CKP; X-ray; 2.05 A; A=1-298.
PDB; 1DI8; X-ray; 2.20 A; A=1-298.
PDB; 1DM2; X-ray; 2.10 A; A=1-298.
PDB; 1E1V; X-ray; 1.95 A; A=1-298.
PDB; 1E1X; X-ray; 1.85 A; A=1-298.
PDB; 1E9H; X-ray; 2.50 A; A/C=1-296.
PDB; 1F5Q; X-ray; 2.50 A; A/C=1-298.
PDB; 1FIN; X-ray; 2.30 A; A/C=1-298.
PDB; 1FQ1; X-ray; 3.00 A; B=1-298.
PDB; 1FVT; X-ray; 2.20 A; A=1-298.
PDB; 1FVV; X-ray; 2.80 A; A/C=1-298.
PDB; 1G5S; X-ray; 2.61 A; A=1-298.
PDB; 1GIH; X-ray; 2.80 A; A=1-298.
PDB; 1GII; X-ray; 2.00 A; A=1-298.
PDB; 1GIJ; X-ray; 2.20 A; A=1-298.
PDB; 1GY3; X-ray; 2.70 A; A/C=1-296.
PDB; 1GZ8; X-ray; 1.30 A; A=1-298.
PDB; 1H00; X-ray; 1.60 A; A=1-298.
PDB; 1H01; X-ray; 1.79 A; A=1-298.
PDB; 1H07; X-ray; 1.85 A; A=1-298.
PDB; 1H08; X-ray; 1.80 A; A=1-298.
PDB; 1H0V; X-ray; 1.90 A; A=1-298.
PDB; 1H0W; X-ray; 2.10 A; A=1-298.
PDB; 1H1P; X-ray; 2.10 A; A/C=1-298.
PDB; 1H1Q; X-ray; 2.50 A; A/C=1-298.
PDB; 1H1R; X-ray; 2.00 A; A/C=1-298.
PDB; 1H1S; X-ray; 2.00 A; A/C=1-298.
PDB; 1H24; X-ray; 2.50 A; A/C=1-298.
PDB; 1H25; X-ray; 2.50 A; A/C=1-298.
PDB; 1H26; X-ray; 2.24 A; A/C=1-298.
PDB; 1H27; X-ray; 2.20 A; A/C=1-298.
PDB; 1H28; X-ray; 2.80 A; A/C=1-298.
PDB; 1HCK; X-ray; 1.90 A; A=1-298.
PDB; 1HCL; X-ray; 1.80 A; A=1-298.
PDB; 1JST; X-ray; 2.60 A; A/C=1-298.
PDB; 1JSU; X-ray; 2.30 A; A=1-298.
PDB; 1JSV; X-ray; 1.96 A; A=1-298.
PDB; 1JVP; X-ray; 1.53 A; P=1-298.
PDB; 1KE5; X-ray; 2.20 A; A=1-298.
PDB; 1KE6; X-ray; 2.00 A; A=1-298.
PDB; 1KE7; X-ray; 2.00 A; A=1-298.
PDB; 1KE8; X-ray; 2.00 A; A=1-298.
PDB; 1KE9; X-ray; 2.00 A; A=1-298.
PDB; 1OGU; X-ray; 2.60 A; A/C=1-298.
PDB; 1OI9; X-ray; 2.10 A; A/C=1-298.
PDB; 1OIQ; X-ray; 2.31 A; A=1-298.
PDB; 1OIR; X-ray; 1.91 A; A=1-298.
PDB; 1OIT; X-ray; 1.60 A; A=1-298.
PDB; 1OIU; X-ray; 2.00 A; A/C=1-298.
PDB; 1OIY; X-ray; 2.40 A; A/C=1-298.
PDB; 1OKV; X-ray; 2.40 A; A/C=1-298.
PDB; 1OKW; X-ray; 2.50 A; A/C=1-298.
PDB; 1OL1; X-ray; 2.90 A; A/C=1-298.
PDB; 1OL2; X-ray; 2.60 A; A/C=1-298.
PDB; 1P2A; X-ray; 2.50 A; A=1-298.
PDB; 1P5E; X-ray; 2.22 A; A/C=1-298.
PDB; 1PF8; X-ray; 2.51 A; A=1-298.
PDB; 1PKD; X-ray; 2.30 A; A/C=1-296.
PDB; 1PW2; X-ray; 1.95 A; A=1-298.
PDB; 1PXI; X-ray; 1.95 A; A=1-298.
PDB; 1PXJ; X-ray; 2.30 A; A=1-298.
PDB; 1PXK; X-ray; 2.80 A; A=1-298.
PDB; 1PXL; X-ray; 2.50 A; A=1-298.
PDB; 1PXM; X-ray; 2.53 A; A=1-298.
PDB; 1PXN; X-ray; 2.50 A; A=1-298.
PDB; 1PXO; X-ray; 1.96 A; A=1-298.
PDB; 1PXP; X-ray; 2.30 A; A=1-298.
PDB; 1PYE; X-ray; 2.00 A; A=1-298.
PDB; 1QMZ; X-ray; 2.20 A; A/C=1-298.
PDB; 1R78; X-ray; 2.00 A; A=1-298.
PDB; 1URC; X-ray; 2.60 A; A/C=1-298.
PDB; 1URW; X-ray; 1.60 A; A=1-298.
PDB; 1V1K; X-ray; 2.31 A; A=1-298.
PDB; 1VYW; X-ray; 2.30 A; A/C=1-298.
PDB; 1VYZ; X-ray; 2.21 A; A=1-298.
PDB; 1W0X; X-ray; 2.20 A; C=1-298.
PDB; 1W8C; X-ray; 2.05 A; A=1-298.
PDB; 1W98; X-ray; 2.15 A; A=1-297.
PDB; 1WCC; X-ray; 2.20 A; A=1-298.
PDB; 1Y8Y; X-ray; 2.00 A; A=1-298.
PDB; 1Y91; X-ray; 2.15 A; A=1-298.
PDB; 1YKR; X-ray; 1.80 A; A=1-298.
PDB; 2A0C; X-ray; 1.95 A; X=1-298.
PDB; 2A4L; X-ray; 2.40 A; A=1-298.
PDB; 2B52; X-ray; 1.88 A; A=1-298.
PDB; 2B53; X-ray; 2.00 A; A=1-298.
PDB; 2B54; X-ray; 1.85 A; A=1-298.
PDB; 2B55; X-ray; 1.85 A; A=1-298.
PDB; 2BHE; X-ray; 1.90 A; A=1-298.
PDB; 2BHH; X-ray; 2.60 A; A=1-298.
PDB; 2BKZ; X-ray; 2.60 A; A/C=1-298.
PDB; 2BPM; X-ray; 2.40 A; A/C=1-298.
PDB; 2BTR; X-ray; 1.85 A; A=1-298.
PDB; 2BTS; X-ray; 1.99 A; A=1-298.
PDB; 2C4G; X-ray; 2.70 A; A/C=1-298.
PDB; 2C5N; X-ray; 2.10 A; A/C=1-298.
PDB; 2C5O; X-ray; 2.10 A; A/C=1-298.
PDB; 2C5V; X-ray; 2.90 A; A/C=1-298.
PDB; 2C5X; X-ray; 2.90 A; A/C=1-298.
PDB; 2C5Y; X-ray; 2.25 A; A=1-298.
PDB; 2C68; X-ray; 1.95 A; A=1-298.
PDB; 2C69; X-ray; 2.10 A; A=1-298.
PDB; 2C6I; X-ray; 1.80 A; A=1-298.
PDB; 2C6K; X-ray; 1.90 A; A=1-298.
PDB; 2C6L; X-ray; 2.30 A; A=1-298.
PDB; 2C6M; X-ray; 1.90 A; A=1-298.
PDB; 2C6O; X-ray; 2.10 A; A=1-298.
PDB; 2C6T; X-ray; 2.61 A; A/C=1-298.
PDB; 2CCH; X-ray; 1.70 A; A/C=1-298.
PDB; 2CCI; X-ray; 2.70 A; A/C=1-298.
PDB; 2CJM; X-ray; 2.30 A; A/C=1-298.
PDB; 2CLX; X-ray; 1.80 A; A=1-298.
PDB; 2DS1; X-ray; 2.00 A; A=1-298.
PDB; 2DUV; X-ray; 2.20 A; A=1-298.
PDB; 2EXM; X-ray; 1.80 A; A=1-298.
PDB; 2FVD; X-ray; 1.85 A; A=1-298.
PDB; 2G9X; X-ray; 2.50 A; A/C=1-298.
PDB; 2HIC; Model; -; A=1-298.
PDB; 2I40; X-ray; 2.80 A; A/C=1-298.
PDB; 2IW6; X-ray; 2.30 A; A/C=1-298.
PDB; 2IW8; X-ray; 2.30 A; A/C=1-298.
PDB; 2IW9; X-ray; 2.00 A; A/C=1-298.
PDB; 2J9M; X-ray; 2.50 A; A=1-298.
PDB; 2JGZ; X-ray; 2.90 A; A=1-288.
PDB; 2R3F; X-ray; 1.50 A; A=1-298.
PDB; 2R3G; X-ray; 1.55 A; A=1-298.
PDB; 2R3H; X-ray; 1.50 A; A=1-298.
PDB; 2R3I; X-ray; 1.28 A; A=1-298.
PDB; 2R3J; X-ray; 1.65 A; A=1-298.
PDB; 2R3K; X-ray; 1.70 A; A=1-298.
PDB; 2R3L; X-ray; 1.65 A; A=1-298.
PDB; 2R3M; X-ray; 1.70 A; A=1-298.
PDB; 2R3N; X-ray; 1.63 A; A=1-298.
PDB; 2R3O; X-ray; 1.80 A; A=1-298.
PDB; 2R3P; X-ray; 1.66 A; A=1-298.
PDB; 2R3Q; X-ray; 1.35 A; A=1-298.
PDB; 2R3R; X-ray; 1.47 A; A=1-298.
PDB; 2R64; X-ray; 2.30 A; A=1-298.
PDB; 2UUE; X-ray; 2.06 A; A/C=1-298.
PDB; 2UZB; X-ray; 2.70 A; A/C=1-298.
PDB; 2UZD; X-ray; 2.72 A; A/C=1-298.
PDB; 2UZE; X-ray; 2.40 A; A/C=1-298.
PDB; 2UZL; X-ray; 2.40 A; A/C=1-298.
PDB; 2UZN; X-ray; 2.30 A; A=1-298.
PDB; 2UZO; X-ray; 2.30 A; A=1-298.
PDB; 2V0D; X-ray; 2.20 A; A=1-298.
PDB; 2V22; X-ray; 2.60 A; A/C=1-298.
PDB; 2VTA; X-ray; 2.00 A; A=1-298.
PDB; 2VTH; X-ray; 1.90 A; A=1-298.
PDB; 2VTI; X-ray; 2.00 A; A=1-298.
PDB; 2VTJ; X-ray; 2.20 A; A=1-298.
PDB; 2VTL; X-ray; 2.00 A; A=1-298.
PDB; 2VTM; X-ray; 2.25 A; A=1-298.
PDB; 2VTN; X-ray; 2.20 A; A=1-298.
PDB; 2VTO; X-ray; 2.19 A; A=1-298.
PDB; 2VTP; X-ray; 2.15 A; A=1-298.
PDB; 2VTQ; X-ray; 1.90 A; A=1-298.
PDB; 2VTR; X-ray; 1.90 A; A=1-298.
PDB; 2VTS; X-ray; 1.90 A; A=1-298.
PDB; 2VTT; X-ray; 1.68 A; A=1-298.
PDB; 2VU3; X-ray; 1.85 A; A=1-298.
PDB; 2VV9; X-ray; 1.90 A; A=1-298.
PDB; 2W05; X-ray; 1.90 A; A=1-298.
PDB; 2W06; X-ray; 2.04 A; A=1-298.
PDB; 2W17; X-ray; 2.15 A; A=1-298.
PDB; 2W1H; X-ray; 2.15 A; A=1-298.
PDB; 2WEV; X-ray; 2.30 A; A/C=1-298.
PDB; 2WFY; X-ray; 2.53 A; A/C=1-298.
PDB; 2WHB; X-ray; 2.90 A; A/C=1-298.
PDB; 2WIH; X-ray; 2.50 A; A/C=1-298.
PDB; 2WIP; X-ray; 2.80 A; A/C=1-298.
PDB; 2WMA; X-ray; 2.80 A; A/C=1-298.
PDB; 2WMB; X-ray; 2.60 A; A/C=1-298.
PDB; 2WPA; X-ray; 2.51 A; A/C=1-298.
PDB; 2WXV; X-ray; 2.60 A; A/C=1-298.
PDB; 2X1N; X-ray; 2.75 A; A/C=1-298.
PDB; 2XMY; X-ray; 1.90 A; A=1-298.
PDB; 2XNB; X-ray; 1.85 A; A=1-298.
PDB; 3BHT; X-ray; 2.00 A; A/C=1-298.
PDB; 3BHU; X-ray; 2.30 A; A/C=1-298.
PDB; 3BHV; X-ray; 2.10 A; A/C=1-298.
PDB; 3DDP; X-ray; 2.70 A; A/C=1-298.
PDB; 3DDQ; X-ray; 1.80 A; A/C=1-298.
PDB; 3DOG; X-ray; 2.70 A; A/C=1-298.
PDB; 3EID; X-ray; 3.15 A; A/C=1-298.
PDB; 3EJ1; X-ray; 3.22 A; A/C=1-298.
PDB; 3EOC; X-ray; 3.20 A; A/C=1-298.
PDB; 3EZR; X-ray; 1.90 A; A=1-298.
PDB; 3EZV; X-ray; 1.99 A; A=1-298.
PDB; 3F5X; X-ray; 2.40 A; A/C=1-298.
PDB; 3FZ1; X-ray; 1.90 A; A=1-298.
PDB; 3IG7; X-ray; 1.80 A; A=1-298.
PDB; 3IGG; X-ray; 1.80 A; A=1-298.
PDB; 3LE6; X-ray; 2.00 A; A=1-298.
PDB; 3LFN; X-ray; 2.28 A; A=1-298.
PDB; 3LFQ; X-ray; 2.03 A; A=1-298.
PDB; 3LFS; X-ray; 2.40 A; A=1-298.
PDB; 3MY5; X-ray; 2.10 A; A/C=1-298.
PDB; 3NS9; X-ray; 1.78 A; A=1-298.
PDB; 3PJ8; X-ray; 1.96 A; A=1-298.
PDB; 3PXF; X-ray; 1.80 A; A=1-298.
PDB; 3PXQ; X-ray; 1.90 A; A=1-298.
PDB; 3PXR; X-ray; 2.00 A; A=1-298.
PDB; 3PXY; X-ray; 1.80 A; A=1-298.
PDB; 3PXZ; X-ray; 1.70 A; A=1-298.
PDB; 3PY0; X-ray; 1.75 A; A=1-298.
PDB; 3PY1; X-ray; 2.05 A; A=1-298.
PDB; 3QHR; X-ray; 2.17 A; A/C=1-296.
PDB; 3QHW; X-ray; 1.91 A; A/C=1-296.
PDB; 3QL8; X-ray; 1.90 A; A=1-298.
PDB; 3QQF; X-ray; 1.75 A; A=1-298.
PDB; 3QQG; X-ray; 1.90 A; A=1-298.
PDB; 3QQH; X-ray; 1.87 A; A=1-298.
PDB; 3QQJ; X-ray; 1.70 A; A=1-298.
PDB; 3QQK; X-ray; 1.86 A; A=1-298.
PDB; 3QQL; X-ray; 1.85 A; A=1-298.
PDB; 3QRT; X-ray; 1.75 A; A=1-298.
PDB; 3QRU; X-ray; 1.95 A; A=1-298.
PDB; 3QTQ; X-ray; 1.80 A; A=1-298.
PDB; 3QTR; X-ray; 1.85 A; A=1-298.
PDB; 3QTS; X-ray; 1.90 A; A=1-298.
PDB; 3QTU; X-ray; 1.82 A; A=1-298.
PDB; 3QTW; X-ray; 1.85 A; A=1-298.
PDB; 3QTX; X-ray; 1.95 A; A=1-298.
PDB; 3QTZ; X-ray; 2.00 A; A=1-298.
PDB; 3QU0; X-ray; 1.95 A; A=1-298.
PDB; 3QWJ; X-ray; 1.75 A; A=1-298.
PDB; 3QWK; X-ray; 1.85 A; A=1-298.
PDB; 3QX2; X-ray; 1.75 A; A=1-298.
PDB; 3QX4; X-ray; 1.92 A; A=1-298.
PDB; 3QXO; X-ray; 1.75 A; A=1-298.
PDB; 3QXP; X-ray; 1.75 A; A=1-298.
PDB; 3QZF; X-ray; 2.00 A; A=1-298.
PDB; 3QZG; X-ray; 1.75 A; A=1-298.
PDB; 3QZH; X-ray; 1.95 A; A=1-298.
PDB; 3QZI; X-ray; 1.75 A; A=1-298.
PDB; 3R1Q; X-ray; 1.85 A; A=1-298.
PDB; 3R1S; X-ray; 1.80 A; A=1-298.
PDB; 3R1Y; X-ray; 1.80 A; A=1-298.
PDB; 3R28; X-ray; 1.75 A; A=1-298.
PDB; 3R6X; X-ray; 1.75 A; A=1-298.
PDB; 3R71; X-ray; 1.75 A; A=1-298.
PDB; 3R73; X-ray; 1.70 A; A=1-298.
PDB; 3R7E; X-ray; 1.90 A; A=1-298.
PDB; 3R7I; X-ray; 1.85 A; A=1-298.
PDB; 3R7U; X-ray; 1.75 A; A=1-298.
PDB; 3R7V; X-ray; 1.95 A; A=1-298.
PDB; 3R7Y; X-ray; 1.90 A; A=1-298.
PDB; 3R83; X-ray; 1.75 A; A=1-298.
PDB; 3R8L; X-ray; 1.90 A; A=1-298.
PDB; 3R8M; X-ray; 1.80 A; A=1-298.
PDB; 3R8P; X-ray; 1.80 A; A=1-298.
PDB; 3R8U; X-ray; 2.00 A; A=1-298.
PDB; 3R8V; X-ray; 1.90 A; A=1-298.
PDB; 3R8Z; X-ray; 1.85 A; A=1-298.
PDB; 3R9D; X-ray; 1.95 A; A=1-298.
PDB; 3R9H; X-ray; 2.10 A; A=1-298.
PDB; 3R9N; X-ray; 1.75 A; A=1-298.
PDB; 3R9O; X-ray; 1.90 A; A=1-298.
PDB; 3RAH; X-ray; 1.75 A; A=1-298.
PDB; 3RAI; X-ray; 1.70 A; A=1-298.
PDB; 3RAK; X-ray; 1.75 A; A=1-298.
PDB; 3RAL; X-ray; 1.75 A; A=1-298.
PDB; 3RJC; X-ray; 1.85 A; A=1-298.
PDB; 3RK5; X-ray; 2.00 A; A=1-298.
PDB; 3RK7; X-ray; 1.80 A; A=1-298.
PDB; 3RK9; X-ray; 1.85 A; A=1-298.
PDB; 3RKB; X-ray; 2.00 A; A=1-298.
PDB; 3RM6; X-ray; 1.60 A; A=1-298.
PDB; 3RM7; X-ray; 1.85 A; A=1-298.
PDB; 3RMF; X-ray; 1.75 A; A=1-298.
PDB; 3RNI; X-ray; 1.95 A; A=1-298.
PDB; 3ROY; X-ray; 1.75 A; A=1-298.
PDB; 3RPO; X-ray; 1.75 A; A=1-298.
PDB; 3RPR; X-ray; 1.75 A; A=1-298.
PDB; 3RPV; X-ray; 1.80 A; A=1-298.
PDB; 3RPY; X-ray; 1.90 A; A=1-298.
PDB; 3RZB; X-ray; 1.90 A; A=1-298.
PDB; 3S00; X-ray; 1.80 A; A=1-298.
PDB; 3S0O; X-ray; 2.00 A; A=1-298.
PDB; 3S1H; X-ray; 1.75 A; A=1-298.
PDB; 3S2P; X-ray; 2.30 A; A=1-298.
PDB; 3SQQ; X-ray; 1.85 A; A=1-298.
PDB; 3SW4; X-ray; 1.70 A; A=1-298.
PDB; 3SW7; X-ray; 1.80 A; A=1-298.
PDB; 3TI1; X-ray; 1.99 A; A=1-298.
PDB; 3TIY; X-ray; 1.84 A; A=1-298.
PDB; 3TIZ; X-ray; 2.02 A; A=1-298.
PDB; 3TNW; X-ray; 2.00 A; A/C=1-298.
PDB; 3ULI; X-ray; 2.00 A; A=1-298.
PDB; 3UNJ; X-ray; 1.90 A; A=1-298.
PDB; 3UNK; X-ray; 2.10 A; A=1-298.
PDB; 3WBL; X-ray; 2.00 A; A=1-298.
PDB; 4ACM; X-ray; 1.63 A; A=1-298.
PDB; 4BCK; X-ray; 2.05 A; A/C=1-298.
PDB; 4BCM; X-ray; 2.45 A; A/C=1-298.
PDB; 4BCN; X-ray; 2.10 A; A/C=1-298.
PDB; 4BCO; X-ray; 2.05 A; A/C=1-298.
PDB; 4BCP; X-ray; 2.26 A; A/C=1-298.
PDB; 4BCQ; X-ray; 2.40 A; A/C=1-298.
PDB; 4BGH; X-ray; 1.95 A; A=1-298.
PDB; 4BZD; X-ray; 1.83 A; A=1-298.
PDB; 4CFM; X-ray; 2.85 A; A/C=1-298.
PDB; 4CFN; X-ray; 2.20 A; A/C=1-298.
PDB; 4CFU; X-ray; 2.20 A; A/C=1-298.
PDB; 4CFV; X-ray; 2.00 A; A/C=1-298.
PDB; 4CFW; X-ray; 2.45 A; A/C=1-298.
PDB; 4CFX; X-ray; 3.50 A; A/C=1-298.
PDB; 4D1X; X-ray; 2.10 A; A=1-298.
PDB; 4D1Z; X-ray; 1.85 A; A=1-298.
PDB; 4EK3; X-ray; 1.34 A; A=1-298.
PDB; 4EK4; X-ray; 1.26 A; A=1-298.
PDB; 4EK5; X-ray; 1.60 A; A=1-298.
PDB; 4EK6; X-ray; 1.52 A; A=1-298.
PDB; 4EK8; X-ray; 1.70 A; A=1-298.
PDB; 4EOI; X-ray; 2.00 A; A/C=1-298.
PDB; 4EOJ; X-ray; 1.65 A; A/C=1-298.
PDB; 4EOK; X-ray; 2.57 A; A/C=1-297.
PDB; 4EOL; X-ray; 2.40 A; A/C=1-297.
PDB; 4EOM; X-ray; 2.10 A; A/C=1-297.
PDB; 4EON; X-ray; 2.40 A; A/C=1-298.
PDB; 4EOO; X-ray; 2.10 A; A/C=1-297.
PDB; 4EOP; X-ray; 1.99 A; A/C=1-297.
PDB; 4EOQ; X-ray; 2.15 A; A/C=1-297.
PDB; 4EOR; X-ray; 2.20 A; A/C=1-297.
PDB; 4EOS; X-ray; 2.57 A; A/C=1-297.
PDB; 4ERW; X-ray; 2.00 A; A=1-298.
PDB; 4EZ3; X-ray; 2.00 A; A=1-298.
PDB; 4EZ7; X-ray; 2.49 A; A=1-298.
PDB; 4FKG; X-ray; 1.51 A; A=1-298.
PDB; 4FKI; X-ray; 1.60 A; A=1-298.
PDB; 4FKJ; X-ray; 1.63 A; A=1-298.
PDB; 4FKL; X-ray; 1.26 A; A=1-298.
PDB; 4FKO; X-ray; 1.55 A; A=1-298.
PDB; 4FKP; X-ray; 1.60 A; A=1-298.
PDB; 4FKQ; X-ray; 1.75 A; A=1-298.
PDB; 4FKR; X-ray; 1.90 A; A=1-298.
PDB; 4FKS; X-ray; 1.55 A; A=1-298.
PDB; 4FKT; X-ray; 1.60 A; A=1-298.
PDB; 4FKU; X-ray; 1.47 A; A=1-298.
PDB; 4FKV; X-ray; 1.70 A; A=1-298.
PDB; 4FKW; X-ray; 1.80 A; A=1-298.
PDB; 4FX3; X-ray; 2.75 A; A/C=1-298.
PDB; 4GCJ; X-ray; 1.42 A; A=1-298.
PDB; 4I3Z; X-ray; 2.05 A; A/C=1-296.
PDB; 4II5; X-ray; 2.15 A; A/C=1-298.
PDB; 4KD1; X-ray; 1.70 A; A=1-298.
PDB; 4LYN; X-ray; 2.00 A; A=1-298.
PDB; 4NJ3; X-ray; 1.85 A; A=1-298.
PDB; 4RJ3; X-ray; 1.63 A; A=1-298.
PDB; 5A14; X-ray; 2.00 A; A=1-298.
PDB; 5AND; X-ray; 2.30 A; A=1-298.
PDB; 5ANE; X-ray; 1.70 A; A=1-298.
PDB; 5ANG; X-ray; 1.90 A; A=1-298.
PDB; 5ANI; X-ray; 1.90 A; A=1-298.
PDB; 5ANJ; X-ray; 1.60 A; A=1-298.
PDB; 5ANK; X-ray; 1.90 A; A=1-298.
PDB; 5ANO; X-ray; 1.70 A; A=1-298.
PDB; 5CYI; X-ray; 2.00 A; A/C=1-298.
PDB; 5D1J; X-ray; 1.80 A; A=1-298.
PDB; 5FP5; X-ray; 2.16 A; A=1-298.
PDB; 5FP6; X-ray; 1.85 A; A=1-298.
PDB; 5IEV; X-ray; 2.03 A; A=1-298.
PDB; 5IEX; X-ray; 2.03 A; A=1-298.
PDB; 5IEY; X-ray; 1.66 A; A=1-298.
PDB; 5IF1; X-ray; 2.61 A; A/C=1-298.
PDB; 5JQ5; X-ray; 1.94 A; A=1-298.
PDB; 5JQ8; X-ray; 1.94 A; A=1-298.
PDB; 5K4J; X-ray; 1.60 A; A=1-298.
PDB; 5L2W; X-ray; 2.80 A; A=1-298.
PDB; 5LMK; X-ray; 2.40 A; A=1-298, C=1-296.
PDB; 5MHQ; X-ray; 1.30 A; A=1-298.
PDB; 5NEV; X-ray; 2.97 A; A/C=1-298.
PDB; 5OO0; X-ray; 1.60 A; A=1-298.
PDB; 5OO1; X-ray; 2.00 A; A=1-298.
PDB; 5OO3; X-ray; 1.73 A; A=1-298.
PDB; 5OSJ; X-ray; 1.83 A; A=1-298.
PDB; 5OSM; X-ray; 1.77 A; A=1-298.
PDB; 5UQ1; X-ray; 3.20 A; A/C=1-298.
PDB; 5UQ2; X-ray; 2.70 A; A=1-298.
PDB; 5UQ3; X-ray; 3.60 A; A=1-298.
PDB; 6ATH; X-ray; 1.82 A; A=1-298.
PDB; 6GUB; X-ray; 2.52 A; A/C=1-298.
PDB; 6GUC; X-ray; 2.00 A; A/C=1-298.
PDB; 6GUE; X-ray; 1.99 A; A/C=1-298.
PDB; 6GUF; X-ray; 2.65 A; A/C=1-298.
PDB; 6GUH; X-ray; 1.50 A; A=1-298.
PDB; 6GUK; X-ray; 1.30 A; A=1-298.
PDB; 6GVA; X-ray; 2.15 A; A=1-298.
PDB; 6INL; X-ray; 1.75 A; A=1-298.
PDB; 6JGM; X-ray; 2.30 A; A=1-298.
PDB; 6P3W; X-ray; 2.54 A; A/C=1-298.
PDB; 6Q3B; X-ray; 1.11 A; A=1-298.
PDB; 6Q3C; X-ray; 1.29 A; A=1-298.
PDB; 6Q3F; X-ray; 1.18 A; A=1-298.
PDB; 6Q48; X-ray; 1.03 A; A=1-298.
PDB; 6Q49; X-ray; 1.00 A; A=1-298.
PDB; 6Q4A; X-ray; 1.13 A; A=1-298.
PDB; 6Q4B; X-ray; 1.12 A; A=1-298.
PDB; 6Q4C; X-ray; 1.73 A; A=1-298.
PDB; 6Q4D; X-ray; 1.07 A; A=1-298.
PDB; 6Q4E; X-ray; 1.06 A; A=1-298.
PDB; 6Q4F; X-ray; 1.21 A; A=1-298.
PDB; 6Q4G; X-ray; 0.98 A; A=1-298.
PDB; 6Q4H; X-ray; 1.00 A; A=1-298.
PDB; 6Q4I; X-ray; 1.11 A; A=1-298.
PDB; 6Q4J; X-ray; 1.05 A; A=1-298.
PDB; 6Q4K; X-ray; 1.06 A; A=1-298.
PDBsum; 1AQ1; -.
PDBsum; 1B38; -.
PDBsum; 1B39; -.
PDBsum; 1BUH; -.
PDBsum; 1CKP; -.
PDBsum; 1DI8; -.
PDBsum; 1DM2; -.
PDBsum; 1E1V; -.
PDBsum; 1E1X; -.
PDBsum; 1E9H; -.
PDBsum; 1F5Q; -.
PDBsum; 1FIN; -.
PDBsum; 1FQ1; -.
PDBsum; 1FVT; -.
PDBsum; 1FVV; -.
PDBsum; 1G5S; -.
PDBsum; 1GIH; -.
PDBsum; 1GII; -.
PDBsum; 1GIJ; -.
PDBsum; 1GY3; -.
PDBsum; 1GZ8; -.
PDBsum; 1H00; -.
PDBsum; 1H01; -.
PDBsum; 1H07; -.
PDBsum; 1H08; -.
PDBsum; 1H0V; -.
PDBsum; 1H0W; -.
PDBsum; 1H1P; -.
PDBsum; 1H1Q; -.
PDBsum; 1H1R; -.
PDBsum; 1H1S; -.
PDBsum; 1H24; -.
PDBsum; 1H25; -.
PDBsum; 1H26; -.
PDBsum; 1H27; -.
PDBsum; 1H28; -.
PDBsum; 1HCK; -.
PDBsum; 1HCL; -.
PDBsum; 1JST; -.
PDBsum; 1JSU; -.
PDBsum; 1JSV; -.
PDBsum; 1JVP; -.
PDBsum; 1KE5; -.
PDBsum; 1KE6; -.
PDBsum; 1KE7; -.
PDBsum; 1KE8; -.
PDBsum; 1KE9; -.
PDBsum; 1OGU; -.
PDBsum; 1OI9; -.
PDBsum; 1OIQ; -.
PDBsum; 1OIR; -.
PDBsum; 1OIT; -.
PDBsum; 1OIU; -.
PDBsum; 1OIY; -.
PDBsum; 1OKV; -.
PDBsum; 1OKW; -.
PDBsum; 1OL1; -.
PDBsum; 1OL2; -.
PDBsum; 1P2A; -.
PDBsum; 1P5E; -.
PDBsum; 1PF8; -.
PDBsum; 1PKD; -.
PDBsum; 1PW2; -.
PDBsum; 1PXI; -.
PDBsum; 1PXJ; -.
PDBsum; 1PXK; -.
PDBsum; 1PXL; -.
PDBsum; 1PXM; -.
PDBsum; 1PXN; -.
PDBsum; 1PXO; -.
PDBsum; 1PXP; -.
PDBsum; 1PYE; -.
PDBsum; 1QMZ; -.
PDBsum; 1R78; -.
PDBsum; 1URC; -.
PDBsum; 1URW; -.
PDBsum; 1V1K; -.
PDBsum; 1VYW; -.
PDBsum; 1VYZ; -.
PDBsum; 1W0X; -.
PDBsum; 1W8C; -.
PDBsum; 1W98; -.
PDBsum; 1WCC; -.
PDBsum; 1Y8Y; -.
PDBsum; 1Y91; -.
PDBsum; 1YKR; -.
PDBsum; 2A0C; -.
PDBsum; 2A4L; -.
PDBsum; 2B52; -.
PDBsum; 2B53; -.
PDBsum; 2B54; -.
PDBsum; 2B55; -.
PDBsum; 2BHE; -.
PDBsum; 2BHH; -.
PDBsum; 2BKZ; -.
PDBsum; 2BPM; -.
PDBsum; 2BTR; -.
PDBsum; 2BTS; -.
PDBsum; 2C4G; -.
PDBsum; 2C5N; -.
PDBsum; 2C5O; -.
PDBsum; 2C5V; -.
PDBsum; 2C5X; -.
PDBsum; 2C5Y; -.
PDBsum; 2C68; -.
PDBsum; 2C69; -.
PDBsum; 2C6I; -.
PDBsum; 2C6K; -.
PDBsum; 2C6L; -.
PDBsum; 2C6M; -.
PDBsum; 2C6O; -.
PDBsum; 2C6T; -.
PDBsum; 2CCH; -.
PDBsum; 2CCI; -.
PDBsum; 2CJM; -.
PDBsum; 2CLX; -.
PDBsum; 2DS1; -.
PDBsum; 2DUV; -.
PDBsum; 2EXM; -.
PDBsum; 2FVD; -.
PDBsum; 2G9X; -.
PDBsum; 2HIC; -.
PDBsum; 2I40; -.
PDBsum; 2IW6; -.
PDBsum; 2IW8; -.
PDBsum; 2IW9; -.
PDBsum; 2J9M; -.
PDBsum; 2JGZ; -.
PDBsum; 2R3F; -.
PDBsum; 2R3G; -.
PDBsum; 2R3H; -.
PDBsum; 2R3I; -.
PDBsum; 2R3J; -.
PDBsum; 2R3K; -.
PDBsum; 2R3L; -.
PDBsum; 2R3M; -.
PDBsum; 2R3N; -.
PDBsum; 2R3O; -.
PDBsum; 2R3P; -.
PDBsum; 2R3Q; -.
PDBsum; 2R3R; -.
PDBsum; 2R64; -.
PDBsum; 2UUE; -.
PDBsum; 2UZB; -.
PDBsum; 2UZD; -.
PDBsum; 2UZE; -.
PDBsum; 2UZL; -.
PDBsum; 2UZN; -.
PDBsum; 2UZO; -.
PDBsum; 2V0D; -.
PDBsum; 2V22; -.
PDBsum; 2VTA; -.
PDBsum; 2VTH; -.
PDBsum; 2VTI; -.
PDBsum; 2VTJ; -.
PDBsum; 2VTL; -.
PDBsum; 2VTM; -.
PDBsum; 2VTN; -.
PDBsum; 2VTO; -.
PDBsum; 2VTP; -.
PDBsum; 2VTQ; -.
PDBsum; 2VTR; -.
PDBsum; 2VTS; -.
PDBsum; 2VTT; -.
PDBsum; 2VU3; -.
PDBsum; 2VV9; -.
PDBsum; 2W05; -.
PDBsum; 2W06; -.
PDBsum; 2W17; -.
PDBsum; 2W1H; -.
PDBsum; 2WEV; -.
PDBsum; 2WFY; -.
PDBsum; 2WHB; -.
PDBsum; 2WIH; -.
PDBsum; 2WIP; -.
PDBsum; 2WMA; -.
PDBsum; 2WMB; -.
PDBsum; 2WPA; -.
PDBsum; 2WXV; -.
PDBsum; 2X1N; -.
PDBsum; 2XMY; -.
PDBsum; 2XNB; -.
PDBsum; 3BHT; -.
PDBsum; 3BHU; -.
PDBsum; 3BHV; -.
PDBsum; 3DDP; -.
PDBsum; 3DDQ; -.
PDBsum; 3DOG; -.
PDBsum; 3EID; -.
PDBsum; 3EJ1; -.
PDBsum; 3EOC; -.
PDBsum; 3EZR; -.
PDBsum; 3EZV; -.
PDBsum; 3F5X; -.
PDBsum; 3FZ1; -.
PDBsum; 3IG7; -.
PDBsum; 3IGG; -.
PDBsum; 3LE6; -.
PDBsum; 3LFN; -.
PDBsum; 3LFQ; -.
PDBsum; 3LFS; -.
PDBsum; 3MY5; -.
PDBsum; 3NS9; -.
PDBsum; 3PJ8; -.
PDBsum; 3PXF; -.
PDBsum; 3PXQ; -.
PDBsum; 3PXR; -.
PDBsum; 3PXY; -.
PDBsum; 3PXZ; -.
PDBsum; 3PY0; -.
PDBsum; 3PY1; -.
PDBsum; 3QHR; -.
PDBsum; 3QHW; -.
PDBsum; 3QL8; -.
PDBsum; 3QQF; -.
PDBsum; 3QQG; -.
PDBsum; 3QQH; -.
PDBsum; 3QQJ; -.
PDBsum; 3QQK; -.
PDBsum; 3QQL; -.
PDBsum; 3QRT; -.
PDBsum; 3QRU; -.
PDBsum; 3QTQ; -.
PDBsum; 3QTR; -.
PDBsum; 3QTS; -.
PDBsum; 3QTU; -.
PDBsum; 3QTW; -.
PDBsum; 3QTX; -.
PDBsum; 3QTZ; -.
PDBsum; 3QU0; -.
PDBsum; 3QWJ; -.
PDBsum; 3QWK; -.
PDBsum; 3QX2; -.
PDBsum; 3QX4; -.
PDBsum; 3QXO; -.
PDBsum; 3QXP; -.
PDBsum; 3QZF; -.
PDBsum; 3QZG; -.
PDBsum; 3QZH; -.
PDBsum; 3QZI; -.
PDBsum; 3R1Q; -.
PDBsum; 3R1S; -.
PDBsum; 3R1Y; -.
PDBsum; 3R28; -.
PDBsum; 3R6X; -.
PDBsum; 3R71; -.
PDBsum; 3R73; -.
PDBsum; 3R7E; -.
PDBsum; 3R7I; -.
PDBsum; 3R7U; -.
PDBsum; 3R7V; -.
PDBsum; 3R7Y; -.
PDBsum; 3R83; -.
PDBsum; 3R8L; -.
PDBsum; 3R8M; -.
PDBsum; 3R8P; -.
PDBsum; 3R8U; -.
PDBsum; 3R8V; -.
PDBsum; 3R8Z; -.
PDBsum; 3R9D; -.
PDBsum; 3R9H; -.
PDBsum; 3R9N; -.
PDBsum; 3R9O; -.
PDBsum; 3RAH; -.
PDBsum; 3RAI; -.
PDBsum; 3RAK; -.
PDBsum; 3RAL; -.
PDBsum; 3RJC; -.
PDBsum; 3RK5; -.
PDBsum; 3RK7; -.
PDBsum; 3RK9; -.
PDBsum; 3RKB; -.
PDBsum; 3RM6; -.
PDBsum; 3RM7; -.
PDBsum; 3RMF; -.
PDBsum; 3RNI; -.
PDBsum; 3ROY; -.
PDBsum; 3RPO; -.
PDBsum; 3RPR; -.
PDBsum; 3RPV; -.
PDBsum; 3RPY; -.
PDBsum; 3RZB; -.
PDBsum; 3S00; -.
PDBsum; 3S0O; -.
PDBsum; 3S1H; -.
PDBsum; 3S2P; -.
PDBsum; 3SQQ; -.
PDBsum; 3SW4; -.
PDBsum; 3SW7; -.
PDBsum; 3TI1; -.
PDBsum; 3TIY; -.
PDBsum; 3TIZ; -.
PDBsum; 3TNW; -.
PDBsum; 3ULI; -.
PDBsum; 3UNJ; -.
PDBsum; 3UNK; -.
PDBsum; 3WBL; -.
PDBsum; 4ACM; -.
PDBsum; 4BCK; -.
PDBsum; 4BCM; -.
PDBsum; 4BCN; -.
PDBsum; 4BCO; -.
PDBsum; 4BCP; -.
PDBsum; 4BCQ; -.
PDBsum; 4BGH; -.
PDBsum; 4BZD; -.
PDBsum; 4CFM; -.
PDBsum; 4CFN; -.
PDBsum; 4CFU; -.
PDBsum; 4CFV; -.
PDBsum; 4CFW; -.
PDBsum; 4CFX; -.
PDBsum; 4D1X; -.
PDBsum; 4D1Z; -.
PDBsum; 4EK3; -.
PDBsum; 4EK4; -.
PDBsum; 4EK5; -.
PDBsum; 4EK6; -.
PDBsum; 4EK8; -.
PDBsum; 4EOI; -.
PDBsum; 4EOJ; -.
PDBsum; 4EOK; -.
PDBsum; 4EOL; -.
PDBsum; 4EOM; -.
PDBsum; 4EON; -.
PDBsum; 4EOO; -.
PDBsum; 4EOP; -.
PDBsum; 4EOQ; -.
PDBsum; 4EOR; -.
PDBsum; 4EOS; -.
PDBsum; 4ERW; -.
PDBsum; 4EZ3; -.
PDBsum; 4EZ7; -.
PDBsum; 4FKG; -.
PDBsum; 4FKI; -.
PDBsum; 4FKJ; -.
PDBsum; 4FKL; -.
PDBsum; 4FKO; -.
PDBsum; 4FKP; -.
PDBsum; 4FKQ; -.
PDBsum; 4FKR; -.
PDBsum; 4FKS; -.
PDBsum; 4FKT; -.
PDBsum; 4FKU; -.
PDBsum; 4FKV; -.
PDBsum; 4FKW; -.
PDBsum; 4FX3; -.
PDBsum; 4GCJ; -.
PDBsum; 4I3Z; -.
PDBsum; 4II5; -.
PDBsum; 4KD1; -.
PDBsum; 4LYN; -.
PDBsum; 4NJ3; -.
PDBsum; 4RJ3; -.
PDBsum; 5A14; -.
PDBsum; 5AND; -.
PDBsum; 5ANE; -.
PDBsum; 5ANG; -.
PDBsum; 5ANI; -.
PDBsum; 5ANJ; -.
PDBsum; 5ANK; -.
PDBsum; 5ANO; -.
PDBsum; 5CYI; -.
PDBsum; 5D1J; -.
PDBsum; 5FP5; -.
PDBsum; 5FP6; -.
PDBsum; 5IEV; -.
PDBsum; 5IEX; -.
PDBsum; 5IEY; -.
PDBsum; 5IF1; -.
PDBsum; 5JQ5; -.
PDBsum; 5JQ8; -.
PDBsum; 5K4J; -.
PDBsum; 5L2W; -.
PDBsum; 5LMK; -.
PDBsum; 5MHQ; -.
PDBsum; 5NEV; -.
PDBsum; 5OO0; -.
PDBsum; 5OO1; -.
PDBsum; 5OO3; -.
PDBsum; 5OSJ; -.
PDBsum; 5OSM; -.
PDBsum; 5UQ1; -.
PDBsum; 5UQ2; -.
PDBsum; 5UQ3; -.
PDBsum; 6ATH; -.
PDBsum; 6GUB; -.
PDBsum; 6GUC; -.
PDBsum; 6GUE; -.
PDBsum; 6GUF; -.
PDBsum; 6GUH; -.
PDBsum; 6GUK; -.
PDBsum; 6GVA; -.
PDBsum; 6INL; -.
PDBsum; 6JGM; -.
PDBsum; 6P3W; -.
PDBsum; 6Q3B; -.
PDBsum; 6Q3C; -.
PDBsum; 6Q3F; -.
PDBsum; 6Q48; -.
PDBsum; 6Q49; -.
PDBsum; 6Q4A; -.
PDBsum; 6Q4B; -.
PDBsum; 6Q4C; -.
PDBsum; 6Q4D; -.
PDBsum; 6Q4E; -.
PDBsum; 6Q4F; -.
PDBsum; 6Q4G; -.
PDBsum; 6Q4H; -.
PDBsum; 6Q4I; -.
PDBsum; 6Q4J; -.
PDBsum; 6Q4K; -.
SMR; P24941; -.
BioGRID; 107452; 721.
ComplexPortal; CPX-2005; Cyclin A1-CDK2 complex.
ComplexPortal; CPX-2006; Cyclin A2-CDK2 complex.
ComplexPortal; CPX-2009; Cyclin B3-CDK2 complex.
ComplexPortal; CPX-2015; Cyclin E1-CDK2 complex.
ComplexPortal; CPX-2016; Cyclin E2-CDK2 complex.
CORUM; P24941; -.
DIP; DIP-161N; -.
ELM; P24941; -.
IntAct; P24941; 174.
MINT; P24941; -.
STRING; 9606.ENSP00000266970; -.
BindingDB; P24941; -.
ChEMBL; CHEMBL301; -.
DrugBank; DB06888; (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE.
DrugBank; DB03583; (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one.
DrugBank; DB07054; (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL.
DrugBank; DB07750; (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol.
DrugBank; DB07761; (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol.
DrugBank; DB07504; (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol.
DrugBank; DB08463; (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol.
DrugBank; DB08285; (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol.
DrugBank; DB07889; (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol.
DrugBank; DB07755; (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol.
DrugBank; DB07751; (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol.
DrugBank; DB07501; (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol.
DrugBank; DB07137; (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide.
DrugBank; DB07431; (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one.
DrugBank; DB08137; (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide.
DrugBank; DB02963; (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine.
DrugBank; DB06983; (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol.
DrugBank; DB07529; (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one.
DrugBank; DB02898; (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone.
DrugBank; DB07595; (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE.
DrugBank; DB07852; 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID.
DrugBank; DB07622; 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA.
DrugBank; DB06976; 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA.
DrugBank; DB03663; 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol.
DrugBank; DB08527; 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE.
DrugBank; DB02603; 1-Amino-6-Cyclohex-3-Enylmethyloxypurine.
DrugBank; DB08355; 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid.
DrugBank; DB07024; 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE.
DrugBank; DB07618; 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE.
DrugBank; DB04288; 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine.
DrugBank; DB02297; 2-Amino-6-Chloropyrazine.
DrugBank; DB06948; 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE.
DrugBank; DB07982; 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol.
DrugBank; DB07179; 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide.
DrugBank; DB08248; 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE.
DrugBank; DB08309; 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL.
DrugBank; DB04518; 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol.
DrugBank; DB08535; 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB07210; 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB08536; 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine.
DrugBank; DB08537; 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine.
DrugBank; DB08539; 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB08533; 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine.
DrugBank; DB03490; 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole.
DrugBank; DB08124; 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one.
DrugBank; DB08126; 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole.
DrugBank; DB03737; 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One.
DrugBank; DB02915; 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine.
DrugBank; DB02091; 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine.
DrugBank; DB03019; 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine.
DrugBank; DB08178; 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine.
DrugBank; DB08182; 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine.
DrugBank; DB02973; 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide.
DrugBank; DB08241; 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE.
DrugBank; DB08136; 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide.
DrugBank; DB07687; 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE.
DrugBank; DB02197; 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide.
DrugBank; DB08673; 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE.
DrugBank; DB03307; 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide.
DrugBank; DB08134; 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide.
DrugBank; DB06844; 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE.
DrugBank; DB03365; 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline.
DrugBank; DB04407; 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol.
DrugBank; DB01888; 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide.
DrugBank; DB08219; 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine.
DrugBank; DB07540; 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE.
DrugBank; DB07531; 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE.
DrugBank; DB07533; 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE.
DrugBank; DB07538; 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE.
DrugBank; DB07534; 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE.
DrugBank; DB07539; 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID.
DrugBank; DB08141; 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide.
DrugBank; DB08125; 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide.
DrugBank; DB07791; 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE.
DrugBank; DB08572; 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE.
DrugBank; DB07686; 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE.
DrugBank; DB07685; 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE.
DrugBank; DB07688; 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE.
DrugBank; DB07065; 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB08531; 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB08534; 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB07163; 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE.
DrugBank; DB08140; 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE.
DrugBank; DB07471; 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE.
DrugBank; DB07493; 5-Bromoindirubin.
DrugBank; DB08139; 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile.
DrugBank; DB08132; 5-hydroxynaphthalene-1-sulfonamide.
DrugBank; DB08532; 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine.
DrugBank; DB07606; 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE.
DrugBank; DB07612; 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE.
DrugBank; DB08247; 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE.
DrugBank; DB08441; 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE.
DrugBank; DB07203; 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE.
DrugBank; DB08233; 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE.
DrugBank; DB08312; 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE.
DrugBank; DB02407; 6-O-Cyclohexylmethyl Guanine.
DrugBank; DB04006; [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone.
DrugBank; DB02833; [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine.
DrugBank; DB03496; Alvocidib.
DrugBank; DB08142; AT-7519.
DrugBank; DB06616; Bosutinib.
DrugBank; DB07731; CAN-508.
DrugBank; DB08218; HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM.
DrugBank; DB02950; Hymenialdisine.
DrugBank; DB02052; Indirubin-3'-monoxime.
DrugBank; DB03801; Lysine Nz-Carboxylic Acid.
DrugBank; DB04186; N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea.
DrugBank; DB04101; N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide.
DrugBank; DB08768; N(6)-dimethylallyladenine.
DrugBank; DB08538; N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine.
DrugBank; DB07790; N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE.
DrugBank; DB06944; N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide.
DrugBank; DB08133; N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide.
DrugBank; DB07936; N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine.
DrugBank; DB02647; N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide.
DrugBank; DB08677; N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide.
DrugBank; DB08066; N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE.
DrugBank; DB07562; N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE.
DrugBank; DB02538; N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide.
DrugBank; DB07220; N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE.
DrugBank; DB07164; N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine.
DrugBank; DB08122; N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide.
DrugBank; DB08123; N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide.
DrugBank; DB08135; N-phenyl-1H-pyrazole-3-carboxamide.
DrugBank; DB07126; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE.
DrugBank; DB02116; Olomoucine.
DrugBank; DB04662; OLOMOUCINE II.
DrugBank; DB04607; PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE.
DrugBank; DB02733; Purvalanol.
DrugBank; DB08094; RO-4584820.
DrugBank; DB06195; Seliciclib.
DrugBank; DB02010; Staurosporine.
DrugBank; DB03428; SU9516.
DrugBank; DB04669; TRIAZOLOPYRIMIDINE.
DrugBank; DB08694; Variolin B.
DrugBank; DB08138; {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide.
DrugCentral; P24941; -.
GuidetoPHARMACOLOGY; 1973; -.
iPTMnet; P24941; -.
PhosphoSitePlus; P24941; -.
SwissPalm; P24941; -.
BioMuta; CDK2; -.
DMDM; 116051; -.
EPD; P24941; -.
jPOST; P24941; -.
MassIVE; P24941; -.
MaxQB; P24941; -.
PaxDb; P24941; -.
PeptideAtlas; P24941; -.
PRIDE; P24941; -.
ProteomicsDB; 54241; -. [P24941-1]
ProteomicsDB; 54242; -. [P24941-2]
Antibodypedia; 3404; 1642 antibodies.
DNASU; 1017; -.
Ensembl; ENST00000266970; ENSP00000266970; ENSG00000123374. [P24941-1]
Ensembl; ENST00000354056; ENSP00000243067; ENSG00000123374. [P24941-2]
GeneID; 1017; -.
KEGG; hsa:1017; -.
UCSC; uc001sit.5; human. [P24941-1]
CTD; 1017; -.
DisGeNET; 1017; -.
EuPathDB; HostDB:ENSG00000123374.10; -.
GeneCards; CDK2; -.
HGNC; HGNC:1771; CDK2.
HPA; ENSG00000123374; Low tissue specificity.
MIM; 116953; gene.
neXtProt; NX_P24941; -.
OpenTargets; ENSG00000123374; -.
PharmGKB; PA101; -.
eggNOG; KOG0594; Eukaryota.
GeneTree; ENSGT00940000159517; -.
HOGENOM; CLU_000288_181_1_1; -.
InParanoid; P24941; -.
KO; K02206; -.
PhylomeDB; P24941; -.
TreeFam; TF101021; -.
BRENDA; 2.7.11.22; 2681.
PathwayCommons; P24941; -.
Reactome; R-HSA-1538133; G0 and Early G1.
Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
Reactome; R-HSA-176408; Regulation of APC/C activators between G1/S and early anaphase.
Reactome; R-HSA-187577; SCF(Skp2)-mediated degradation of p27/p21.
Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
Reactome; R-HSA-68911; G2 Phase.
Reactome; R-HSA-68949; Orc1 removal from chromatin.
Reactome; R-HSA-68962; Activation of the pre-replicative complex.
Reactome; R-HSA-69017; CDK-mediated phosphorylation and removal of Cdc6.
Reactome; R-HSA-69200; Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes.
Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
Reactome; R-HSA-69273; Cyclin A/B1/B2 associated events during G2/M transition.
Reactome; R-HSA-69563; p53-Dependent G1 DNA Damage Response.
Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
Reactome; R-HSA-8849470; PTK6 Regulates Cell Cycle.
Reactome; R-HSA-912446; Meiotic recombination.
Reactome; R-HSA-9616222; Transcriptional regulation of granulopoiesis.
Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
SignaLink; P24941; -.
SIGNOR; P24941; -.
BioGRID-ORCS; 1017; 500 hits in 912 CRISPR screens.
ChiTaRS; CDK2; human.
EvolutionaryTrace; P24941; -.
GeneWiki; Cyclin-dependent_kinase_2; -.
GenomeRNAi; 1017; -.
Pharos; P24941; Tchem.
PRO; PR:P24941; -.
Proteomes; UP000005640; Chromosome 12.
RNAct; P24941; protein.
Bgee; ENSG00000123374; Expressed in ventricular zone and 214 other tissues.
ExpressionAtlas; P24941; baseline and differential.
Genevisible; P24941; HS.
GO; GO:0015030; C:Cajal body; IDA:UniProtKB.
GO; GO:0005813; C:centrosome; IDA:HPA.
GO; GO:0000781; C:chromosome, telomeric region; IEA:Ensembl.
GO; GO:0000793; C:condensed chromosome; IEA:Ensembl.
GO; GO:0097123; C:cyclin A1-CDK2 complex; IDA:UniProtKB.
GO; GO:0097124; C:cyclin A2-CDK2 complex; IDA:UniProtKB.
GO; GO:0097134; C:cyclin E1-CDK2 complex; IDA:UniProtKB.
GO; GO:0097135; C:cyclin E2-CDK2 complex; IDA:UniProtKB.
GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:UniProtKB.
GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
GO; GO:0005829; C:cytosol; TAS:Reactome.
GO; GO:0005768; C:endosome; IDA:UniProtKB.
GO; GO:0005654; C:nucleoplasm; IDA:CAFA.
GO; GO:0005634; C:nucleus; IDA:UniProtKB.
GO; GO:0005667; C:transcription regulator complex; IEA:Ensembl.
GO; GO:0000805; C:X chromosome; IEA:Ensembl.
GO; GO:0000806; C:Y chromosome; IEA:Ensembl.
GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
GO; GO:0030332; F:cyclin binding; IDA:UniProtKB.
GO; GO:0097472; F:cyclin-dependent protein kinase activity; IDA:UniProtKB.
GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
GO; GO:0000287; F:magnesium ion binding; IEA:Ensembl.
GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
GO; GO:0004674; F:protein serine/threonine kinase activity; IGI:ARUK-UCL.
GO; GO:0031145; P:anaphase-promoting complex-dependent catabolic process; TAS:Reactome.
GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
GO; GO:0071732; P:cellular response to nitric oxide; TAS:UniProtKB.
GO; GO:0007099; P:centriole replication; IMP:UniProtKB.
GO; GO:0051298; P:centrosome duplication; TAS:UniProtKB.
GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
GO; GO:0006260; P:DNA replication; TAS:UniProtKB.
GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IBA:GO_Central.
GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
GO; GO:0016572; P:histone phosphorylation; IDA:CAFA.
GO; GO:0051321; P:meiotic cell cycle; TAS:UniProtKB.
GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; TAS:UniProtKB.
GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
GO; GO:0032298; P:positive regulation of DNA-dependent DNA replication initiation; IEA:Ensembl.
GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
GO; GO:0006813; P:potassium ion transport; IEA:Ensembl.
GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
GO; GO:0010389; P:regulation of G2/M transition of mitotic cell cycle; IBA:GO_Central.
GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
GO; GO:0060968; P:regulation of gene silencing; IDA:UniProtKB.
GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
IDEAL; IID00034; -.
InterPro; IPR011009; Kinase-like_dom_sf.
InterPro; IPR000719; Prot_kinase_dom.
InterPro; IPR017441; Protein_kinase_ATP_BS.
InterPro; IPR008271; Ser/Thr_kinase_AS.
Pfam; PF00069; Pkinase; 1.
SMART; SM00220; S_TKc; 1.
SUPFAM; SSF56112; SSF56112; 1.
PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
1: Evidence at protein level;
3D-structure; Acetylation; Alternative splicing; ATP-binding; Cell cycle;
Cell division; Cytoplasm; Cytoskeleton; DNA damage; DNA repair; Endosome;
Kinase; Magnesium; Meiosis; Metal-binding; Mitosis; Nucleotide-binding;
Nucleus; Phosphoprotein; Polymorphism; Reference proteome; S-nitrosylation;
Serine/threonine-protein kinase; Transferase.
CHAIN 1..298
/note="Cyclin-dependent kinase 2"
/id="PRO_0000085769"
DOMAIN 4..286
/note="Protein kinase"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
NP_BIND 10..18
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
NP_BIND 81..83
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
NP_BIND 129..132
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
ACT_SITE 127
/note="Proton acceptor"
METAL 132
/note="Magnesium"
/evidence="ECO:0000269|PubMed:21565702"
METAL 145
/note="Magnesium"
/evidence="ECO:0000269|PubMed:21565702"
BINDING 33
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
BINDING 86
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
BINDING 145
/note="ATP"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:21565702"
SITE 9
/note="CDK7 binding"
SITE 88..89
/note="CDK7 binding"
SITE 166
/note="CDK7 binding"
MOD_RES 1
/note="N-acetylmethionine"
/evidence="ECO:0000244|PubMed:22814378"
MOD_RES 6
/note="N6-acetyllysine"
/evidence="ECO:0000244|PubMed:19608861"
MOD_RES 14
/note="Phosphothreonine"
/evidence="ECO:0000269|PubMed:1396589,
ECO:0000269|PubMed:17095507"
MOD_RES 15
/note="Phosphotyrosine; by WEE1"
/evidence="ECO:0000244|PubMed:19690332,
ECO:0000269|PubMed:1396589, ECO:0000269|PubMed:17095507"
MOD_RES 19
/note="Phosphotyrosine"
/evidence="ECO:0000244|PubMed:19369195"
MOD_RES 160
/note="Phosphothreonine; by CAK and CCRK"
/evidence="ECO:0000269|PubMed:1396589,
ECO:0000269|PubMed:14597612, ECO:0000269|PubMed:16325401,
ECO:0000269|PubMed:17095507, ECO:0000269|PubMed:17570665,
ECO:0000269|PubMed:20147522, ECO:0000269|PubMed:20360007,
ECO:0000269|PubMed:21565702, ECO:0000305|PubMed:28666995"
VAR_SEQ 163..196
/note="Missing (in isoform 2)"
/evidence="ECO:0000305"
/id="VSP_041998"
VARIANT 15
/note="Y -> S (in dbSNP:rs3087335)"
/id="VAR_016157"
VARIANT 18
/note="V -> L (in dbSNP:rs11554376)"
/id="VAR_053927"
VARIANT 45
/note="P -> L (in a glioblastoma multiforme sample; somatic
mutation)"
/evidence="ECO:0000269|PubMed:17344846"
/id="VAR_041972"
VARIANT 290
/note="T -> S (in dbSNP:rs2069413)"
/evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.6"
/id="VAR_019988"
MUTAGEN 9
/note="K->F: Reduced phosphorylation by CAK."
/evidence="ECO:0000269|PubMed:17373709"
MUTAGEN 14
/note="T->A: 2-fold increase in activity."
/evidence="ECO:0000269|PubMed:1396589"
MUTAGEN 15
/note="Y->F: 2-fold increase in activity."
/evidence="ECO:0000269|PubMed:1396589"
MUTAGEN 88..89
/note="KK->EV: Reduced phosphorylation by CAK."
/evidence="ECO:0000269|PubMed:17373709"
MUTAGEN 160
/note="T->A: Abolishes activity."
/evidence="ECO:0000269|PubMed:1396589"
MUTAGEN 166
/note="L->R: Reduced phosphorylation by CAK and reduced
kinase activity."
/evidence="ECO:0000269|PubMed:17373709"
CONFLICT 8..12
/note="EKIGE -> AQIGQ (in Ref. 5; BAA32794)"
/evidence="ECO:0000305"
CONFLICT 25..29
/note="LTGEV -> STGQM (in Ref. 5; BAA32794)"
/evidence="ECO:0000305"
CONFLICT 272..277
/note="NKRISA -> YKRFST (in Ref. 5; BAA32794)"
/evidence="ECO:0000305"
CONFLICT 286..287
/note="FQ -> LE (in Ref. 5; BAA32794)"
/evidence="ECO:0000305"
STRAND 3..12
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 14..23
/evidence="ECO:0000244|PDB:6Q4G"
TURN 24..26
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 29..34
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 39..41
/evidence="ECO:0000244|PDB:4GCJ"
STRAND 42..44
/evidence="ECO:0000244|PDB:2CCH"
HELIX 46..54
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 55..57
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 66..72
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 75..81
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 84..86
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 87..93
/evidence="ECO:0000244|PDB:6Q4G"
TURN 94..97
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 101..120
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 130..132
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 133..135
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 137..139
/evidence="ECO:0000244|PDB:6Q48"
STRAND 141..143
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 148..152
/evidence="ECO:0000244|PDB:6Q4G"
TURN 153..156
/evidence="ECO:0000244|PDB:6Q4D"
STRAND 159..161
/evidence="ECO:0000244|PDB:3RAI"
HELIX 166..168
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 171..174
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 178..180
/evidence="ECO:0000244|PDB:1OKW"
HELIX 183..198
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 208..219
/evidence="ECO:0000244|PDB:6Q4G"
TURN 224..226
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 230..232
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 248..251
/evidence="ECO:0000244|PDB:6Q4G"
STRAND 252..254
/evidence="ECO:0000244|PDB:1GY3"
HELIX 257..266
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 271..273
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 277..281
/evidence="ECO:0000244|PDB:6Q4G"
HELIX 284..286
/evidence="ECO:0000244|PDB:6Q4G"
TURN 287..289
/evidence="ECO:0000244|PDB:1W98"
SEQUENCE 298 AA; 33930 MW; F90A0F4E70910B51 CRC64;
MENFQKVEKI GEGTYGVVYK ARNKLTGEVV ALKKIRLDTE TEGVPSTAIR EISLLKELNH
PNIVKLLDVI HTENKLYLVF EFLHQDLKKF MDASALTGIP LPLIKSYLFQ LLQGLAFCHS
HRVLHRDLKP QNLLINTEGA IKLADFGLAR AFGVPVRTYT HEVVTLWYRA PEILLGCKYY
STAVDIWSLG CIFAEMVTRR ALFPGDSEID QLFRIFRTLG TPDEVVWPGV TSMPDYKPSF
PKWARQDFSK VVPPLDEDGR SLLSQMLHYD PNKRISAKAA LAHPFFQDVT KPVPHLRL


Related products :

Catalog number Product name Quantity
EIAAB06522 CDC2L6,CDC2-related protein kinase 6,CDK11,CDK19,Cell division cycle 2-like protein kinase 6,Cell division protein kinase 19,Cyclin-dependent kinase 11,Cyclin-dependent kinase 19,Death-preventing kina
EIAAB06524 CAK-kinase p42,CCRK,CDCH,CDK20,CDK-activating kinase p42,Cell cycle-related kinase,Cell division protein kinase 20,Cyclin-dependent kinase 20,Cyclin-dependent protein kinase H,Cyclin-kinase-activating
EIAAB06523 CAK-kinase p42,Ccrk,Cdch,Cdk20,CDK-activating kinase p42,CDK-related protein kinase PNQLARE,Cell cycle-related kinase,Cell division protein kinase 20,Cyclin-dependent kinase 20,Cyclin-dependent protei
EIAAB06533 C-2K,CDC2L4,CDK9,Cell division cycle 2-like protein kinase 4,Cell division protein kinase 9,Cyclin-dependent kinase 9,Homo sapiens,Human,Serine_threonine-protein kinase PITALRE,TAK,Tat-associated kina
EIAAB06263 CDC2L2,CDC2L3,CDK11A,Cell division cycle 2-like protein kinase 2,Cell division protein kinase 11A,Cyclin-dependent kinase 11A,Galactosyltransferase-associated protein kinase p58_GTA,Homo sapiens,Human
EIAAB06264 CDC2L1,CDK11,CDK11B,Cell division cycle 2-like protein kinase 1,Cell division protein kinase 11B,CLK-1,Cyclin-dependent kinase 11B,Galactosyltransferase-associated protein kinase p58_GTA,Homo sapiens,
EIAAB06500 Cdc2l1,Cdk11,Cell division cycle 2-like protein kinase 1,Cell division protein kinase 11,Cyclin-dependent kinase 11,Galactosyltransferase-associated protein kinase p58_GTA,Mouse,Mus musculus,PITSLRE s
EIAAB06506 Bos taurus,Bovine,CDC2L,CDC2L5,CDC2-related protein kinase 5,CDK13,Cell division cycle 2-like protein kinase 5,Cell division protein kinase 13,Cyclin-dependent kinase 13
EIAAB06521 Cdc2l6,CDC2-related protein kinase 6,Cdk19,Cell division cycle 2-like protein kinase 6,Cell division protein kinase 19,Cyclin-dependent kinase 19,Kiaa1028,Mouse,Mus musculus
EIAAB06505 Cdc2l5,CDC2-related protein kinase 5,Cdk13,Cell division cycle 2-like protein kinase 5,Cell division protein kinase 13,Cyclin-dependent kinase 13,Kiaa1791,Mouse,Mus musculus
EIAAB06499 Cdc2l1,Cdk11,Cell division cycle 2-like protein kinase 1,Cell division protein kinase 11,Cyclin-dependent kinase 11,Galactosyltransferase-associated protein kinase p58_GTA,PITSLRE serine_threonine-pro
18-003-44328 Cell division protein kinase 9 - EC 2.7.11.22; EC 2.7.11.23; Cyclin-dependent kinase 9; Serine_threonine-protein kinase PITALRE; C-2K; Cell division cycle 2-like protein kinase 4 Polyclonal 0.1 mg Protein A
EIAAB06507 CDC2L,CDC2L5,CDC2-related protein kinase 5,CDK13,Cell division cycle 2-like protein kinase 5,Cell division protein kinase 13,CHED,Cholinesterase-related cell division controller,Cyclin-dependent kinas
E0739b ELISA kit Bos taurus,Bovine,CDK5,CDKN5,Cell division protein kinase 5,Cyclin-dependent kinase 5,PDPK,Proline-directed protein kinase 33 kDa subunit,Serine_threonine-protein kinase PSSALRE,Tau protein 96T
U0739m CLIA Cdk5,Cdkn5,Cell division protein kinase 5,CR6 protein kinase,CRK6,Crk6,Cyclin-dependent kinase 5,Mouse,Mus musculus,Serine_threonine-protein kinase PSSALRE,Tau protein kinase II catalytic subunit 96T
E0739m ELISA Cdk5,Cdkn5,Cell division protein kinase 5,CR6 protein kinase,CRK6,Crk6,Cyclin-dependent kinase 5,Mouse,Mus musculus,Serine_threonine-protein kinase PSSALRE,Tau protein kinase II catalytic subuni 96T
E0739m ELISA kit Cdk5,Cdkn5,Cell division protein kinase 5,CR6 protein kinase,CRK6,Crk6,Cyclin-dependent kinase 5,Mouse,Mus musculus,Serine_threonine-protein kinase PSSALRE,Tau protein kinase II catalytic s 96T
E0739b ELISA Bos taurus,Bovine,CDK5,CDKN5,Cell division protein kinase 5,Cyclin-dependent kinase 5,PDPK,Proline-directed protein kinase 33 kDa subunit,Serine_threonine-protein kinase PSSALRE,Tau protein kina 96T
U0739b CLIA Bos taurus,Bovine,CDK5,CDKN5,Cell division protein kinase 5,Cyclin-dependent kinase 5,PDPK,Proline-directed protein kinase 33 kDa subunit,Serine_threonine-protein kinase PSSALRE,Tau protein kinas 96T
U1880h CLIA kit 39 kDa protein kinase,CAK,CAK1,CDK7,CDK-activating kinase 1,CDKN7,Cell division protein kinase 7,Cyclin-dependent kinase 7,Homo sapiens,Human,MO15,p39 Mo15,Serine_threonine-protein kinase 1, 96T
E1880h ELISA kit 39 kDa protein kinase,CAK,CAK1,CDK7,CDK-activating kinase 1,CDKN7,Cell division protein kinase 7,Cyclin-dependent kinase 7,Homo sapiens,Human,MO15,p39 Mo15,Serine_threonine-protein kinase 1 96T
U1880h CLIA 39 kDa protein kinase,CAK,CAK1,CDK7,CDK-activating kinase 1,CDKN7,Cell division protein kinase 7,Cyclin-dependent kinase 7,Homo sapiens,Human,MO15,p39 Mo15,Serine_threonine-protein kinase 1,STK1, 96T
E1880h ELISA 39 kDa protein kinase,CAK,CAK1,CDK7,CDK-activating kinase 1,CDKN7,Cell division protein kinase 7,Cyclin-dependent kinase 7,Homo sapiens,Human,MO15,p39 Mo15,Serine_threonine-protein kinase 1,STK1 96T
U1888h CLIA CDC2,CDC28A,CDK1,CDK1,CDKN1,Cell division control protein 2 homolog,Cell division protein kinase 1,Cyclin-dependent kinase 1,Homo sapiens,Human,p34 protein kinase,P34CDC2 96T
U1888h CLIA kit CDC2,CDC28A,CDK1,CDK1,CDKN1,Cell division control protein 2 homolog,Cell division protein kinase 1,Cyclin-dependent kinase 1,Homo sapiens,Human,p34 protein kinase,P34CDC2 96T
Pathways :
WP1493: Carbon assimilation C4 pathway
WP1619: Amino sugar and nucleotide sugar metabolism
WP1625: Base excision repair
WP1844: MAP kinase cascade
WP1653: Galactose metabolism
WP2341: vitamin B1 (thiamin) biosynthesis and salvage pathway
WP1681: Pantothenate and CoA biosynthesis
WP32: Translation Factors
WP1703: Streptomycin biosynthesis
WP2340: Thiamine (vitamin B1) biosynthesis and salvage
WP1567: Glycolysis and Gluconeogenesis
WP1678: Nucleotide excision repair
WP253: Glycolysis
WP1701: Starch and sucrose metabolism
WP1672: Mismatch repair
WP1676: Non-homologous end-joining
WP1946: Cori Cycle
WP1685: Peptidoglycan biosynthesis
WP2292: Chemokine signaling pathway
WP525: Mitochondrial Unfolded-Protein Response
WP1692: Protein export
WP2032: TSH signaling pathway
WP1049: G Protein Signaling Pathways
WP210: Cytoplasmic Ribosomal Proteins
WP1659: Glycine, serine and threonine metabolism

Related Genes :
[CDK2 CDKN2] Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase)
[CDK9 CDC2L4 TAK] Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE) (Tat-associated kinase complex catalytic subunit)
[cdk-2 K03E5.3] Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2)
[Cdk11b Cdc2l1 Cdk11] Cyclin-dependent kinase 11B (Cell division cycle 2-like protein kinase 1) (Cell division protein kinase 11) (Cyclin-dependent kinase 11) (EC 2.7.11.22) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L1)
[cdk1-b cdc2 cdc2x1.2] Cyclin-dependent kinase 1-B (CDK1-B) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog 2) (Cell division control protein 2-B) (Cell division protein kinase 1) (p34 protein kinase 2)
[CDK1 CDC2 CDC28A CDKN1 P34CDC2] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[cdk-9 H25P06.2] Probable cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (Cell division protein kinase 9)
[cdk1-a cdc2-a cdc2x1.1] Cyclin-dependent kinase 1-A (CDK1-A) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog 1) (Cell division control protein 2-A) (Cell division protein kinase 1-A) (p34 protein kinase 1)
[Cdk1 Cdc2 Cdc2a Cdkn1] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[Cdk1 Cdc2 Cdc2a Cdkn1] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[CDK1 CDC2 CDKN1] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[Cdk1 cdc2 CG5363] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[CDK7 CAK CAK1 CDKN7 MO15 STK1] Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (p39 Mo15) (CDK-activating kinase 1) (Cell division protein kinase 7) (Serine/threonine-protein kinase 1) (TFIIH basal transcription factor complex kinase subunit)
[CDK13 CDC2L CDC2L5 CHED KIAA1791] Cyclin-dependent kinase 13 (EC 2.7.11.22) (EC 2.7.11.23) (CDC2-related protein kinase 5) (Cell division cycle 2-like protein kinase 5) (Cell division protein kinase 13) (hCDK13) (Cholinesterase-related cell division controller)
[cdc2 cdk1 swo2 pi002 SPBC11B10.09] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (Cell division control protein 2) (Cell division protein kinase 1) (p34 protein kinase)
[cdk1 cdcB DDB_G0272813] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[Cdk7 Cak Cdkn7 Crk4 Mo15 Mpk-7] Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (P39 Mo15) (CDK-activating kinase) (CR4 protein kinase) (CRK4) (Cell division protein kinase 7) (Protein-tyrosine kinase MPK-7) (TFIIH basal transcription factor complex kinase subunit)
[CDK1 CDC2 CDKN1] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)
[CDK11A CDC2L2 CDC2L3 PITSLREB] Cyclin-dependent kinase 11A (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 2) (Cell division protein kinase 11A) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L2)
[CDK11B CDC2L1 CDK11 PITSLREA PK58] Cyclin-dependent kinase 11B (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 1) (CLK-1) (Cell division protein kinase 11B) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L1) (p58 CLK-1)
[CDC28 CDK1 CAALFM_CR06050WA CaO19.11337 CaO19.3856] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (Cell division control protein 28) (Cell division protein kinase 2)
[cdk2 eg1] Cyclin-dependent kinase 2 (EC 2.7.11.22) (CDC2 homolog Eg1 protein kinase) (Cell division protein kinase 2)
[Cdk7 Cak Cak1 Mo15] Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 protein kinase) (P39 Mo15) (CDK-activating kinase 1) (Cell division protein kinase 7) (TFIIH basal transcription factor complex kinase subunit) (Fragment)
[cdk-5 T27E9.3] Cyclin-dependent-like kinase 5 (EC 2.7.11.1) (Cell division protein kinase 5)
[nimX cdk1 AN4182] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (Cell division control protein 2) (Cell division protein kinase 1) (Never in mitosis protein X)
[CDK2 CDKN7] Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2)
[CDKB1-1 CDC2B At3g54180 F24B22.140] Cyclin-dependent kinase B1-1 (CDKB1;1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog B)
[Cdk2 Cdkn2] Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2)
[Cdk2 Cdkn2] Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2)
[CDC28 CDK1 HSL5 SRM5 YBR160W YBR1211] Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (Cell division control protein 28) (Cell division protein kinase 1)

Bibliography :
[12030783] Perspectives for cancer therapies with cdk2 inhibitors.